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Summary 
Clear cell renal cell carcinoma (ccRCC) is the most common type of renal cell carcinoma. 
The von Hippel-Lindau (VHL) tumour suppressor gene is biallelically inactivated in up to 
90% of sporadic cases of ccRCC. The VHL gene product, pVHL, is involved in the 
regulation of diverse cellular processes whose dysregulation could be imagined to play a 
role in tumour formation. One of the best characterized functions is the post-
transcriptional regulation of HIFα transcription factors which have multiple functions in 
diverse cellular processes. However, loss of pVHL function alone is not sufficient to 
cause tumour formation, indicating that additional cooperating mutations are likely to be 
involved in tumour initiation. We could show that mice with a combined deletion of Vhl 
and Trp53 develop simple and atypical cysts, as well as neoplastic lesions in the kidney. 
However, the latency for development of cysts and tumours was one year, indicating that 
other mutations are most likely necessary for initiation of these lesions. Mouse embryonic 
fibroblasts (MEFs) as well as primary kidney cells undergo senescence upon loss of pVhl 
and we have shown that this effect occurs in a p53-dependent manner as in Vhl/Trp53 
negative cells the senescence phenotype is rescued. However these cells still do not 
have full proliferative capacity compared to p53 null cells indicating that additional cellular 
responses upon loss of Vhl may represent transformational barriers. It remains unknown 
if and how metabolic alterations following loss of pVHL contribute to tumour formation.  
 
We investigated the effects of loss of Vhl in MEFs on glucose and glutamine metabolism 
and their implications for cell transformation. We could show that Vhl negative, as well as 
Vhl/Trp53 deficient MEFs exhibited a Hif1α-dependent Warburg-like metabolic phenotype 
with reduced oxygen consumption and decreased ATP generation. The impaired ATP 
generation appears likely to be the cause of senescence in primary Vhl deficient MEFs 
and the impaired proliferation in Vhl/Trp53 negative cells since knockdown of Hif1a in 
these cells rescued ATP levels, senescence and proliferation. The ATP deficiency was 
sensed by AMPK whose activation decreased mTORC1 signalling. Thus, a selection 
against AMPK and/or mTORC1 may represent the additional step for tumour initiation 
and progression in Vhl/Trp53 deficient cells. Multiple experiments using shRNA based 
knockdowns of Tsc1, Tsc2, Stk11 or Prkaa1 in Vhl/Trp53 deficient MEFs were performed 
but could not confirm this hypothesis as none of these knockdowns promoted enhanced 
proliferation or transformation of these cells. In conclusion, it seems that on top of 
alterations of Vhl and Trp53 and an activation of the mTORC1 pathway additional 
mutations are required for tumour initiation. 
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The second aim of the thesis was to elucidate if the senescence-rescued Vhl/Trp53 null 
cells might use carbons derived from glutamine to fuel their demands for energy and 
metabolic intermediates. First experiments with metabolomic and RNA analysis could not 
clearly answer this question. However, Hif1α-dependent elevated levels of Gls2 in Vhl 
and Vhl/Trp53 deficient MEFs and kidney cells indicate a role for glutamine in Vhl 
depleted cells. Furthermore, knockdown of Gls2 in Vhl/Trp53 deficient MEFs enhanced 
the proliferation of these cells and allowed them to grow in an anchorage independent 
manner. Our studies suggest that Gls2 represents a barrier to transformation of Vhl 
deficient cells. 
 
Another aim of this thesis was to identify the effect of combined loss of Vhl and Rb1 on 
cellular senescence and cellular metabolism and its implication in tumour initiation and 
progression. Combined deletion of Vhl and Rb1 in MEFs rescued Vhl-induced 
senescence and ATP levels and these cells were able to grow in an anchorage 
independent manner. Despite promising results from cell culture studies, the kidney-
specific deletion of Vhl and Rb1 did not lead to the breakdown of normal proliferation in 
mice. While Rb1∆/∆ animals showed micro-cysts and small foci of tubular dysplasia, the 
additional loss of Vhl in fact prevented the growth of hyperplastic lesions. Potentially, 
additional mutations might be necessary to initiate tumour development. In this context, 
the combined deletion of Vhl, Rb1 and Trp53 provides promising results. Already at the 
age of three months neoplasms could be found, which grew in a solid or cystic pattern, 
some with clear cell appearance and some with nuclear atypia. This histological 
appearance could potentially indicate precursor lesions of ccRCC. These lesions are 
larger and occur at a much higher frequency about nine months earlier than the lesions 
that were observed in Vhl/Trp53 null mice. It appears that combined deletion of Vhl, Rb1 
and Trp53 might represent the first mouse model for ccRCC. 
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Zusammenfassung 
Klarzellige Nierenzellkarzinome sind die häufigste Form von Nierenzellkarzinomen. Das 
Tumorsuppressorgen von Hippel-Lindau (VHL) ist in über 90% der sporadisch 
auftretenden klarzelligen Nierenzellkarzinome biallelisch inaktiviert. Das Proteinprodukt 
des VHL Lokus, pVHL, ist an der Regulation diverser zellulärer Prozesse beteiligt. Es 
wäre durchaus vorstellbar, dass die Fehlregulation dieser Abläufe eine wichtige Rolle in 
der Tumorentstehung spielen könnte. Die am besten charakterisierte Funktion ist die 
post-transkriptionelle Regulierung der HIFα Transkriptionsfaktoren, die unterschiedlichste 
Funktionen in einer Vielzahl von zellulären Prozessen einnehmen. Für die 
Tumorentstehung ist der Verlust von pVHL alleine jedoch nicht ausreichend, aller 
Wahrscheinlichkeit nach sind zusätzlich auftretende Mutationen daran mitverantwortlich. 
Wir konnten zeigen, dass Nieren von Mäusen mit einer kombinierten Inaktivierung von 
Vhl und Trp53 einfache und atypische Zysten, sowie neoplastische Läsionen entwickeln. 
Die Latenzzeit für die Entwicklung dieser Zysten und Tumore beträgt jedoch ein Jahr, 
was darauf hindeutet, dass weitere Mutationen für die Entstehung von Läsionen 
notwendig sind. Die Inaktivierung von Vhl führt sowohl in embryonischen Fibroblasten 
von Mäusen (MEFs) als auch in primären Maus-Nierenzellen zu Seneszenz. Dieser 
Effekt ist abhängig von p53, da der seneszente Phänotyp in Vhl/Trp53-defizenten Zellen 
zumindest teilweise überwunden werden kann. Diese Zellen prolifierieren jedoch deutlich 
langsamer als p53-defiziente Zellen. Diese Beobachtungen deuten darauf hin, dass der 
Verlust von Vhl zu zusätzlichen zellulären Rückkopplungsmechanismen führt, die eine 
Transformationsbarriere darstellen können. Es ist immer noch nicht klar, ob und wie die 
metabolischen Veränderungen nach dem Verlust von pVHL zur Tumorentstehung 
beitragen.  
 
In dieser Arbeit sollten die Auswirkungen, die der Verlust von Vhl auf den Glukose und 
Glutamin Metabolismus hat und deren Einfluss auf die zelluläre Transformation ermittelt 
werden. Vhl als auch Vhl/Trp53 negative MEFs weisen in Abhängigkeit von Hif1α einen 
metabolischen Phänotyp mit reduziertem Sauerstoffverbrauch und verminderter ATP 
Gewinnung auf, der einem milden Warburg-Effekt gleicht. Wir vermuten, dass die 
verringerte Bildung von ATP der Grund für die Seneszenz in primären Vhl negativen 
Zellen sein könnte und die Proliferation in Vhl/Trp53-defizienten Zellen beeinträchtigt. 
Der Knockdown von Hif1a hingegen konnte das ATP-Niveau wiederherstellen und 
verhinderte somit die Seneszenz. Veränderungen von ATP werden in der Zelle von 
AMPK wahrgenommen, deren Aktivierung die Signalwirkung von mTORC1 
beeinträchtigt. Die Selektion gegen AMPK und/oder mTORC1 ist möglicherweise ein 
weiterer Schritt der für die Initiierung und Progression von Tumoren in Vhl/Trp53 
8 
 
Knockout Zellen verantwortlich sein könnte. Verschiedene Knockdown-Experimente mit 
Tsc1, Tsc2, Stk11 oder Prkaa1 in Vhl/Trp53 Knockout MEFs konnten diese Hypothese 
nicht weiter bestätigen, denn keiner dieser Knockdowns förderte die Proliferation oder 
Transformation dieser Zellen. Es scheint, dass zusätzlich zur genetischen Manipulation 
von Vhl und Trp53 und der dauerhaften Aktivierung des mTORC1 Signalweges noch 
weitere Mutationen notwendig sind, um Tumore entstehen zuzulassen.  
 
Das nächste Ziel dieser Arbeit war es, zu ermitteln, ob Vhl/Trp53-defiziente Zellen, die 
der Seneszenz entkommen sind, Kohlenstoff aus Glutamin verwenden, um ihren Bedarf 
an Energie und metabolischen Intermediaten zu decken. Erste Metabolom- und mRNA-
Expressions-Analysen konnten diese Frage nicht eindeutig beantworten. Die erhöhte 
Hif1α-abhängige Genexpression von Gls2 in Vhl und Vhl/Trp53-defizienten MEFs und 
Nierenzellen deutet jedoch auf eine Rolle für Glutamin in diesen Zellen hin. Des Weiteren 
förderte der Knockdown von Gls2 in Vhl/Trp53-negativen MEFs deren Proliferation und 
ermöglichte das Wachstum ohne Oberflächenzellkontakt. Unsere Studien lassen 
vermuten, dass Gls2 eine Barriere für die Transformation von Vhl negativen Zellen 
darstellt. 
 
Ein weiteres Ziel dieser Arbeit war es, die Auswirkungen, die der kombinierte Verlust von  
Vhl und Rb1 auf die zelluläre Seneszenz und den Zellmetabolismus haben, zu ermitteln. 
Ausserdem untersuchen wir deren Einfluss auf die Entstehung und Weiterentwicklung 
von Tumoren. Die gleichzeitige Inaktivierung von Vhl und Rb1 in MEFs verhinderte die 
durch den Verlust von Vhl induzierte Seneszenz. Diese Zellen zeigten einen 
normalisierten ATP-Spiegel und konnten ohne Oberflächenzellkontakt wachsen. Trotz 
vielversprechender Resultate aus den Zellkultur-Studien führte die nierenspezifische 
Deletion von Vhl und Rb1 in Mäusen nicht zu unkontrolliertem Zellwachstum. Während 
Rb1∆/∆ Tiere Mikrozysten und kleine Herde tubulärer Dysplasie aufwiesen, verhinderte 
die zusätzliche Deletion von Vhl das Wachstum wuchernder Läsionen. Dies zeigt, dass 
zusätzliche Mutationen für die Einleitung der Tumorentstehung notwendig sind. In 
diesem Zusammenhang liefert der kombinierte Verlust von Vhl, Rb1 und Trp53 
vielversprechende Resultate. Bereits nach drei Monaten konnten Neoplasmen entdeckt 
werden, die in einem soliden oder zystischen Muster wuchsen, einige mit klarzelliger 
Morphologie und einige mit nuklearen Atypismen. Dieses histologische Erscheinen 
könnte auf Vorgänger-Läsionen von klarzelligen Nierenzellkarzinomen hindeuten. Die 
gesehenen Läsionen sind bereits neun Monate früher als in Vhl/Trp53-negativen Mäusen 
anzutreffen, sind grösser und treten häufiger auf. Möglicherweise kann die kombinierte 
Inaktivierung von Vhl, Rb1 und Trp53 zum ersten Mausmodel für klarzellige 
Nierenzellkarzinome werden.  
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1 Introduction 
1.1 Kidney cancer 
Cancer is the second most frequent cause of death in the industrial world. Kidney 
cancers account for approximately 3% of all human cancers. Renal cell carcinomas 
(RCCs) are the most common type of malignancies in the kidney, accounting for over 
90% of the cases. Besides hereditary cases, the common risk factors for RCC are 
tobacco smoking, obesity, hypertension and chronic kidney failure. Renal carcinomas 
arise from the epithelium of renal tubules. The majority of adult RCCs are classified as 
clear cell renal cell carcinomas (70%), with papillary (10-15%), chromophobe (5%) and 
collecting duct (< 1%) renal cell carcinomas accounting for the other subtypes (Eble et al. 
2004). However, a recent update of the classifications identified five new epithelial 
tumour subtypes: acquired cystic disease-associated renal cell carcinoma, tubulocystic 
renal cell carcinoma, hereditary leiomyomatosis RCC (HLRCC) syndrome-associated 
RCC and clear cell papillary RCC and MiTF-translocation RCC (Srigley et al. 2013). 
These tumors display very distinct characteristics, leading to different prognoses and 
treatments within the different subtypes. The majority of RCC occur sporadically, but 
2-4% of the cases are linked with inherited tumour syndromes.  
 
1.1.1 The von Hippel-Lindau syndrome 
The autosomal-dominant von Hippel-Lindau (VHL) disease is the most frequent familial 
renal cancer syndrome (Moch 2013). It is characterized by hemangioblastoma of the 
central nervous system and retina, phaeochromocytoma, pancreatic islet cell and inner 
ear tumours, as well as renal cysts and clear cell renal cell carcinomas (ccRCC) (Maher 
and Kaelin 1997). Sequencing has shown that germ-line mutations of the tumour 
suppressor gene VHL, located on chromosome 3p25, are the trigger of this disease 
(Seizinger et al. 1988; Latif et al. 1993). People with this syndrome inherit one defective 
allele of VHL either due to a deletion of the gene or missense or splicing defects and the 
remaining wild-type allele is thereafter somatically inactivated or lost (Stolle et al. 1998). 
This conforms to the Knudson 2-hit model, which postulates that both alleles of a tumour 
suppressor have to be mutated for a cell to become cancerous. Every VHL patient has 
an individual predisposition to different types of benign and malignant tumours based on 
the type of mutation that has been inherited and accordingly the treatment and prognosis 
will differ greatly from patient to patient. As the VHL disease has a strong genotype-
phenotype correlation the families are subdivided in two groups dependent on their risk 
for phaeochromocytoma. Type 1 VHL disease is characterised by the complete loss of 
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VHL function or mutations that affect the protein folding and low risk for 
phaeochromocytoma. The two subtypes of type 1 have either a low risk (type 1A) or a 
high risk (type 1B) for renal cell carcinoma. Type 2 VHL disease displays a high risk for 
phaeochromocytoma and is mainly caused by missense mutations. It can be further 
divided dependent on its risk for renal cell carcinomas, which is low in type 2A, high in 
type 2B and extremely low in type 2C (Zbar et al. 1996; Hes et al. 2000; Kaelin 2002).  
 
1.1.2 Clear cell renal cell carcinoma 
Clear cell renal cell carcinomas are a typical manifestation of the inherited VHL cancer 
syndrome but these tumours also occur sporadically and account for the majority of 
cases of this disease (Foster et al. 1994; Maher and Kaelin 1997). In up to 92% of 
sporadic ccRCCs, the VHL gene is biallelically inactivated (Foster et al. 1994; Sato et al. 
2013). Similarly to ccRCCs in VHL patients this occurs through an allelic deletion or loss 
of heterozygosity on chromosome 3p (Zbar et al. 1987) and concomitant VHL mutation 
(Gnarra et al. 1994) or promoter hypermethylation (Herman et al. 1994). Sato and 
colleagues also identified mutations of TCEB1, the gene encoding Elongin C, which is 
part of the pVHL-ElonginB-ElonginC complex (see section 1.1.3), in a subset of VHL wild 
type ccRCCs, thus inactivating pVHL function through another mechanism (Sato et al. 
2013). Sporadic ccRCCs mainly arise as solitary cortical neoplasms with a yellow tumour 
surface. The appearance of the cells is caused by a high lipid and glycogen content. 
These cells are characterized by clear or eosinophilic cytoplasm with well-defined cell 
borders that is surrounded by a finely branched vascular network (Grignon and Che 
2005; Moch 2013). In addition to solid ccRCCs there are some cases that show a cystic 
appearance. Another subtype, multilocular cystic renal cell carcinoma does not exhibit 
any solid tumour elements and has a complete cystic structure (Eble and Bonsib 1998; 
von Teichman et al. 2011).  
 
For the development of familial and sporadic ccRCC the absence of pVHL is in most 
cases the initial event. According to this, the frequency of single cells or multicellular 
clusters with a functional loss of pVHL is extremely high in kidneys of VHL patients 
(Mandriota et al. 2002). Compared to the general population the frequency of cyst and 
tumour development in VHL patients is highly increased. However, in relation to the high 
number of pVHL mutated cells the frequency of cyst or tumour formation in VHL patients 
is very low, implying that other genetic events have to occur to induce tumourigenesis 
from these VHL mutant cells. The cell type or types that serve as the cell of origin of 
ccRCC is still unclear. While most evidence suggests that ccRCC most often arise from 
proximal tubular epithelial cells, some cases exhibit markers of distal tubules or collecting 
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duct cells, suggesting that epithelial cells from several different nephron segments can 
potentially give rise to ccRCCs (Droz et al. 1990; Paraf et al. 2000; Straube et al. 2011). 
Furthermore the molecular and cellular events that underlie the initiation and progression 
of ccRCC are still an incomplete picture. A number of studies indicate that ccRCC may 
arise via a cyst-dependent pathway in which cysts occur as precursor lesions or may 
arise directly from small solid micro-ccRCC precursor lesions (Thoma et al. 2007; 
Montani et al. 2010). The different ccRCC progression models are shown in Figure 1.1.  
 
 
 
Figure 1.1: Current model of ccRCC development and progression.  
Homozygous loss of VHL occurs frequently in VHL patients but only a small proportion of these VHL null 
cells progress into micro-cysts and the majority of VHL mutant cells appear to remain as single cells or as 
small clusters of cells. Micro-cysts are characterized by upregulated PI3K signalling and loss of the primary 
cilium. Cyst expansion leads to the enlargement of micro-cysts into larger simple cysts that are lined by a 
single epithelial layer. It is believed that some simple cysts can progress to form atypical cysts, which are 
characterized by regions of disorganized and multilayered epithelial growth. It is likely additional pro-
proliferative mutations are needed for the development of cystic ccRCC and probably further mutations may 
turn cystic ccRCC into solid ccRCC. This may occur through neoplastic growth completely filling the former 
cystic lumen. Little is known about the mechanisms by which VHL null cells may progress to form micro-
ccRCC lesions with a solid appearance, which may then directly go on to form solid ccRCC. In summary, it is 
believed that ccRCCs can form via cyst-dependent and cyst-independent precursor lesions. 
 
1.1.3 The von Hippel-Lindau protein 
The human VHL gene encodes a protein with two different isoforms (pVHL30 and pVHL19) 
derived from alternate translational initiation sites, both referred to as pVHL (Iliopoulos et 
al. 1998; Blankenship et al. 1999). pVHL has been ascribed many functions as a 
multipurpose adapter protein regulating a variety of transcriptional as well as other 
cellular processes. pVHL serves as a substrate recognition module of an E3 ubiquitin 
ligase complex consisting of Elongin B, Elongin C, Cullin 2 and Rbx-1 (Pause et al. 1997; 
Lonergan et al. 1998; Kamura et al. 1999; Lisztwan et al. 1999; Stebbins et al. 1999). 
This complex facilitates the proteasomal degradation of the hypoxia-inducible factor α 
(HIFα) transcription factors (Maxwell et al. 1999), as well as the large subunit of the RNA 
polymerase II complex (Rbp1) (Kuznetsova et al. 2003). pVHL also prevents the 
proteolytic degradation of the p53 tumour suppressor protein, an important player in cell 
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cycle arrest and apoptosis (Roe et al. 2006). Another function of pVHL is the inhibition of 
NF-κB transcription factors (Yang et al. 2007) which play a main role in regulating the 
immune system but are also involved in cell survival, differentiation, and proliferation 
(Hayden and Ghosh 2008). Additionally, pVHL supresses several cellular processes like 
cellular senescence (Young et al. 2008; Welford et al. 2010), aneuploidy (Thoma et al. 
2009) and the transition of epithelial to mesenchymal cell characteristics (Esteban et al. 
2006; Pantuck et al. 2010) and is involved in the regulation of neuronal apoptosis (Lee et 
al. 2005), growth factor receptor internalisation (Hsu et al. 2006), degradation of β2-
adrenergic receptors (Xie et al. 2009) and canonical Wnt signalling (Chitalia et al. 2008). 
Furthermore, transcription-independent pVHL functions include deposition of the 
extracellular matrix (Ohh et al. 1998; Kurban et al. 2008) and stabilisation of the 
microtubule cytoskeleton (Hergovich et al. 2003), as well as maintenance of the primary 
cilium (Thoma et al. 2007). It seems quite possible that loss of the above mentioned 
pVHL functions separately or in cooperation can promote tumour initiation. So far it is still 
quite unclear which of the pVHL functions are important for ccRCC progression. In this 
thesis we mainly focused on the role of Vhl with regard to cell metabolism and cell cycle 
regulation. 
 
To analyse the impact of Vhl on ccRCC progression several mouse models with a 
deletion of Vhl were generated. A germ-line mutation of Vhl is accompanied by 
embryonic lethality in homozygous animals due to failures in the vascularisation of the 
placenta (Gnarra et al. 1997). Heterozygous Vhl mutants do not develop kidney tumours 
even under carcinogenic conditions (Kleymenova et al. 2004). Moreover, different mouse 
models with a specific deletion of Vhl in different kidney segments like proximal tubule 
(Rankin et al. 2006), all nephron segments including (Schietke et al. 2012; Mathia et al. 
2013) or excluding the proximal tubules (Frew et al. 2008), as well as in the thick 
ascending loop (Schley et al. 2011) lead to the development of cysts only in some cases 
and no renal tumours were ever observed. Taking these mouse studies into 
consideration and the fact that VHL patients have a multitude of pVHL negative cells that 
apparently never develop into ccRCC tumours, the loss of pVHL alone appears to be 
insufficient for the initiation of ccRCC and other factors and mutations are necessary for 
further progression of VHL mutated cells. ccRCC remains one of the few major human 
tumour types for which no autochthonous mouse model exists. One aim of this thesis 
was to attempt to generate such a mouse model. 
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1.1.4 Hypoxia-inducible factor family 
As already mentioned, the best characterized function of pVHL is in effecting the oxygen-
dependent degradation of HIFα transcription factors. HIFs function as a heterodimeric 
complex consisting of an oxygen-sensitive α-subunit (HIF1α, HIF2α and HIF3α) and a 
stable β-subunit (Maxwell et al. 1999; Ohh et al. 2000; Ivan et al. 2001). HIF1 and HIF2 
α/β heterodimers are involved in the regulation of oxygen-regulated target genes, 
whereas the function for HIF3α is still unclear (Wenger et al. 2005). Under normoxic 
conditions HIFα is hydroxylated by a family of prolyl hydroxylases (PHD1, PDH2 and 
PHD3) and is therefore recognizable for the pVHL-ElonginB-ElonginC complex for 
proteasomal degradation (Tanimoto et al. 2000; Epstein et al. 2001; Ivan et al. 2001). 
Also dependent on oxygen availability is a second mechanism that inhibits HIFα via 
asparaginyl hydroxylation. Under normoxia and mild hypoxia, the factor inhibiting HIF 
(FIH) enzyme hydroxylates the C-terminus of HIFα and transcriptional co-activators like 
p300 and CREB binding protein (CBP) cannot be recruited (Dayan et al. 2006). With 
decreasing oxygen levels PHD and FIH activity is impaired, HIFα can be translocated to 
the nucleus where the HIFα/β complex forms and interacts with co-activators like p300 
and CBP. Once HIF is stabilised it binds to a consensus hypoxia-response element 
(HRE) of the nuclear DNA that is conserved in hundreds of HIF target genes (Wenger et 
al. 2005). These genes are involved in proliferation (e.g. TGFα), glucose/energy 
metabolism (GLUT1, PGK), angiogenesis (VEGF, PDGFβ), apoptosis (BNIP3), 
differentiation (Oct4) and metastasis (CXCR4) (Gordan and Simon 2007). Many HIF 
target genes play important roles in various aspects of tumour biology. HIF1α and HIF2α 
share redundant target genes but also have unique targets that can even have opposing 
effects (Keith et al. 2012).  
 
Recent evidence demonstrates the opposing effects of HIFs on oncoproteins (MYC) and 
tumour suppressors (p53, mTOR), both influencing cell progression on different levels 
(Keith et al. 2012). For example, stabilized HIF1α inhibits MYC and thus limits MYC-
dependent protein synthesis, cell division and anabolic metabolism (Koshiji et al. 2004), 
whereas HIF2α expressing cancer cells enhance MYC activity resulting in increased cell 
proliferation (Gordan et al. 2007). In the development and progression of ccRCC, HIF1α 
and HIF2α also reveal contrasting properties, where HIF1α delays and HIF2α promotes 
tumour development in xenograft studies (Raval et al. 2005). In general, this reflects the 
different impacts of HIF1α and HIF2α function on cell proliferation. Although several 
studies revealed the contribution of HIF1α and HIF2α to ccRCC formation, the 
stabilisation of these proteins alone induced by the loss of VHL is not sufficient for 
tumour formation (Mack et al. 2003). Interestingly, a stable overexpression of HIF1α (Fu 
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et al. 2011), but not HIF2α (Fu et al. 2013), in kidneys was able to generate simple cysts 
but no further tumour development could be detected. These studies also cast new light 
on the contribution of the two HIFα isoforms in tumour initiation, indicating a fundamental 
role for HIF1α in the initiation phase. In summary, beside the loss of VHL and a 
stabilisation of HIFα, other genetic alterations are necessary for tumour initiation, and 
HIFα stabilisation may initially provide an environment that promotes further cancer 
progression only in the presence of additional mutations. In this context of the initial 
stages of tumour formation, we have addressed the question of which effects stabilised 
Hif1α and Hif2α have on the metabolism of Vhl deficient cells.  
 
1.2 Cancer cell metabolism 
In recent years, it has become more and more evident that alterations in cellular 
metabolism are common features of cancerous tissues and are sometimes even required 
for malignant transformation. A multitude of cancer driver mutations have been shown to 
also affect core metabolic signalling pathways and metabolic processes that are 
responsible for tumourigenesis. Cancer cells also have special needs to satisfy cell 
growth and proliferation. Highly proliferating cells require a huge amount of energy 
supported by rapid ATP generation as well as a balanced redox system and adequate 
amounts of macromolecular building blocks (Cairns et al. 2011).  
 
1.2.1 Warburg effect and aerobic glycolysis 
In the presence of oxygen, non-proliferating differentiated cells metabolise glucose to 
pyruvate that is shuttled to the mitochondria to be oxidised in the tricarboxylic acid (TCA) 
cycle for the production of the reducing equivalents NADH and FADH2, which then 
maximises ATP production via oxidative phosphorylation. Under oxygen deprived 
conditions, pyruvate is redirected from the TCA cycle by generating lactate (Vander 
Heiden et al. 2009). A common characteristic of cancer cells, which Warburg already 
described in 1924, is increased anaerobic glycolytic metabolism (Warburg et al. 1924). 
Thereby, the conversion of glucose into lactate even occurs in the presence of sufficient 
oxygen. Warburg’s first hypothesis that a defect in mitochondria caused the impaired 
aerobic respiration in cancer cells was later disproved by several research groups (at 
least for most cancer cells) (Warburg 1956; Moreno-Sánchez et al. 2007). Surprisingly, 
aerobic glycolysis is much less efficient at generating ATP than the oxidative TCA cycle. 
So why would cells choose a less efficient metabolism? Proliferating cells require a large 
amount of nucleotides, amino acids and lipids generated from glucose or glutamine for 
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replication. Directing glucose into the TCA cycle to maximise ATP production would 
therefore release the carbons as carbon dioxide, which are then lost for biosynthesis. 
However, cells using aerobic glycolysis exhibit highly increased glycolytic flux to support 
ATP generation and to simultaneously supply metabolic intermediates for biosynthetic 
processes (Vander Heiden et al. 2009; Cairns et al. 2011).  
 
Glucose transport, aerobic glycolysis and mitochondrial respiration are regulated by the 
HIF1 transcription factor. HIF1 transcriptionally upregulates the glucose transporter 
GLUT1 and important glycolytic enzymes including PGK and LDH-A (Semenza et al. 
1994) and prevents mitochondrial respiration via PDK1 gene upregulation, which in turn 
prevents metabolism of pyruvate to acetyl-CoA (see also Figure 1.2) (Kim et al. 2006; 
Papandreou et al. 2006). Furthermore, HIF1 controls genes that regulate proteins of the 
electron transport chain such as cytochrome c oxidase (Complex IV) (Fukuda et al. 
2007). HIF1 also inhibits Complex I via induction of NDUFA4L2 which is overexpressed 
in VHL-deficient cell lines and therefore decreases mitochondrial oxygenation (Tello et al. 
2011). Moreover, in VHL-negative renal carcinoma cell lines with a constant HIF1 activity 
mitochondrial metabolism and biogenesis are actively repressed by inactivation of C-
MYC activity (Zhang et al. 2007) and reintroduction of VHL causes increased 
mitochondrial electron transport complex activity and increased levels of mitochondrial 
DNA and respiratory chain proteins (Hervouet et al. 2007). Interestingly, increased levels 
of glycolytic enzymes and reduced levels of mitochondrial DNA and respiratory chain 
proteins have also been noted in renal cell carcinoma (Simonnet et al. 2002; Unwin et al. 
2003; Meierhofer et al. 2004). Thus, there is a large amount of evidence for an 
involvement of pVHL in the regulation of glucose metabolism in renal cancer. However, it 
remains unclear if and how pVHL influences metabolism at the initial steps of cancer 
development. The elucidation of this question is one of the central points of this thesis. 
 
 
 
 
 
 
 
Figure 1.2: Cell metabolism 
GLUT1: Glucose transporter, HK: Hexokinase, PGI: Phosphoglucose-isomerase, PFK1: 6-Phosphofructo-1-
kinase, FBP1: Fructose-1,6-bisphosphatase, PFK2: 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase, 
TIGAR: TP53-inducible glycolysis and apoptosis regulator, Aldo: Aldolase, GAPDH: Glyceraldehyde-
phosphate-dehydrogenase, PGK: Phosphoglycerate-kinase, PGM: Phosphoglycerate-mutase, ENO: 
Enolase, PK: Pyruvate-kinase, PDH: Pyruvate-dehydrogenase, LDH-A: Lactate-dehydrogenase, PDK1: 
Pyruvate-dehydrogenase kinase, CS: Citrate-synthase, ACL: ATP-citrate lyase, ACO: Aconitase, IDH: 
Isocitrate-dehydrogenase, α-KGDH: α-Ketoglutarate-dehydrogenase, SUCL: Succinate-CoA ligase, SHD: 
Succinate-dehydrogenase, FH: Fumarase, MDH: Malate-dehydrogenase, GLS: Glutaminase, GLUD: 
Glutamate-dehydrogenase, ASCT2: Glutamine transporter, PPP: Pentose phosphate pathway, TCA: 
tricarboxylic acid cycle. Enzymes in green are HIF1 and C-MYC target genes except of PDK1, which is an 
exclusive HIF1 target. 
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1.2.2 Glutamine metabolism 
To support cell growth and division, glucose and to the same extent glutamine are 
catabolised to supply carbon and nitrogen, free energy and reducing equivalents. 
Glutamine is a non-essential amino acid and the major carrier of nitrogen between 
organs. In proliferating cells it is used for the synthesis of hexosamines, nonessential 
amino acids and nucleotides (DeBerardinis and Cheng 2010). Glutamine is also an 
essential precursor of glutathione that is important for cellular redox balance (Whillier et 
al. 2011). Glutamine-derived carbons can fuel the TCA cycle via α-ketoglutarate and 
oxalacetate for energy demands (DeBerardinis et al. 2008). However, in hypoxic or VHL-
negative cancer cell lines or cells with defective mitochondria, glutamine-derived α-
ketoglutarate is almost exclusively used in the reductive metabolism to generate citrate 
for lipid synthesis. This process is dependent on the presence of isocitrate-
dehydrogenase 1 (IDH1) (cytosolic) or 2 (IDH2) (mitochondrial) (Metallo et al. 2011; 
Mullen et al. 2011; Filipp et al. 2012). This so-called reductive carboxylation is favoured 
in cells with stabilised HIF1α (Metallo et al. 2011; Wise et al. 2011; Gameiro et al. 2013). 
Upon HIF1α stabilisation, the activity of α-ketoglutarate dehydrogenase (α-KGDH) drops 
due to SIAH2 targeted ubiquitination, thus shifting glutamine from oxidative to reductive 
carboxylation (Sun and Denko 2014). One part of this thesis was to identify the 
importance of glutamine for Vhl-deficient cells.    
 
1.2.3 Function of Glutaminases  
The first step in glutaminolysis is the conversion of glutamine to glutamate that is 
performed by an enzyme called glutaminase. In mammals, the glutaminases are 
encoded by two different genes located on separate chromosomes (Aledo et al. 2000). 
The GLS1 gene on chromosome 2 encodes the kidney-type glutaminase (KGA) 
(Curthoys et al. 1976), named after the organ were it was first discovered, and its splice 
variant glutaminase C (GAC) (Elgadi et al. 1999; Porter et al. 2002), both referred to as 
GLS1. KGA is formed by joining exons 1-14 and 16-19 whereas GAC only uses exons 1-
15 (Marquez, Tosina 2009). The other gene GLS2, located on chromosome 12, encodes 
for two forms, liver-type glutaminase (LGA) (Aledo et al. 2000) and its longer variant 
glutaminase B (GAB) that is generated by alternate transcription initiation (de la Rosa et 
al. 2009; Martin-Rufian et al. 2012). The coding sequences of GLS1 and GLS2 show 
extensive similarities, however, two exons only share 62.5% and 29.4% similarity. These 
regions are involved in mitochondrial targeting and translocational processes (Shapiro et 
al. 1991; Gomez-Fabre et al. 2000). The different isoforms display variable kinetic and 
molecular characteristics and are expressed in a diversity of mammalian tissues and 
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cancer cell lines. Therefore, they are either exclusively or co-expressed with one of the 
other isoforms (Aledo et al. 2000; Gomez-Fabre et al. 2000; Perez-Gomez et al. 2005). 
So far, all isoforms have been shown to be confined to the mitochondria, with the 
exception that GAB can also be localised in the nucleus of brain cells, potentially as a 
transcriptional co-regulator (Olalla et al. 2002; Márquez et al. 2006). It seems that 
glutaminases have contrasting roles, especially in tumourigenesis. The expression of 
GLS1 for example is regulated by C-MYC and its overexpression promotes tumour cell 
proliferation (Gao et al. 2009) whereas the loss of GLS1 prevents transformation of cells 
(Lobo et al. 2000). However, GLS2, as a direct p53 target, mediates the tumour-
suppressive effect of p53 in energy metabolism and antioxidant defence (Hu et al. 2010; 
Suzuki et al. 2010). In hepatocellular carcinoma, GLS2 levels are decreased and re-
expression of GLS2 inhibits anchorage-independent cell growth and diminishes the 
growth of xenografts (Liu et al. 2014). It is still not yet fully understood why GLS1 and 
GLS2 isoenzymes that have the same catalytic ability show such differences in their 
biological properties. One possible explanation might be answered by the difference in 
response to phosphate and glutamate. GLS1 is strongly activated by phosphate and 
inhibited by glutamate, whereas GLS2 exhibits a considerably lower degree of phosphate 
dependency and no inhibition by glutamate (Curthoys and Watford 1995). In this thesis 
we examined a so far unknown upregulation of Gls2 in primary mouse embryonic 
fibroblast and kidney cells deficient for Vhl.  
 
1.2.4 Signalling pathways involved in regulation of metabolism in tumour 
cells 
Signalling pathways are important components of the machinery that regulates cellular 
metabolism. Cancer cells often display a multitude of mutations in tumour suppressors 
and oncogenes that affect intracellular signalling pathways. These alterations in 
metabolism of tumour cells are important for enhanced survival and growth and enable 
them to respond to proliferative signals induced by oncogenic signalling pathways. These 
metabolic changes create a new environment that has an important impact on tumour 
progression, response to therapy and patient outcome (Cairns et al. 2011). Recent 
studies provided further verification for dysregulated metabolic pathways in sporadic 
ccRCC. The PI3K-AKT-mTOR pathway is mutationally activated in 26-28% of cases of 
ccRCC. This includes loss of function mutations of negative regulators of the pathway 
like PTEN (phosphatase and tensin homolog), TSC1 or TSC2 (tuberous sclerosis 1 or 2), 
as well as amplifications and activating mutations of positive regulators including 
PIK3CA/B/G, RPS6KA2/3/6, AKT1/2/3, RHEB and MTOR, most of them leading to 
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increased mTORC1 signalling (Sato et al. 2013; TCGA 2013). Further considerations for 
the importance of well-balanced cell homeostasis come from survival correlations. In 
ccRCC, decreased AMPK, decreased TCA cycle activity, an increased dependency on 
the pentose phosphate pathway, increased glutamine transport and increased fatty acid 
production are all involved in a metabolic shift that correlates with disease 
aggressiveness (TCGA 2013). So far it is not clear if and how these alterations are 
required for the initiation progression of ccRCC. 
 
1.2.4.1 Mammalian target of rapamycin 
The master regulator of cell growth and proliferation is the mammalian target of 
rapamycin (mTOR) that is activated by amino acid abundance and growth factor 
signalling, leading to the activation of protein translation and gene expression and the 
inhibition of autophagy (Wullschleger et al. 2006). mTOR is the catalytic component of 
the mTOR complexes, mTORC1 and mTORC2. Common components, besides of 
mTOR, are LST8/GβL and DEPTOR, which function as positive and negative regulators 
of the complex, respectively (Kim et al. 2003; Peterson et al. 2009). Both complexes 
have unique components whereas regulatory-associated protein of mTOR (RAPTOR) 
and Pro-rich Akt substrate (PRAS40) define mTORC1 (Hara et al. 2002; Sancak et al. 
2007). mTORC2 specific components are rapamycin-insensitive companion of mTOR 
(RICTOR) and protein observed with RICTOR 1 and 2 (PROTOR1 and 2) and stress-
activated map kinase-interacting protein 1 (SIN1) (Sarbassov et al. 2004; Pearce et al. 
2007).  
 
The most prominent and best established substrates of mTORC1 are eukaryotic initiation 
factor (eIF) 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1) 
(Hara et al. 1998). To control protein synthesis both proteins are able to associate with 
mRNAs and thus regulate mRNA translation initiation and progression. 
Unphosphorylated 4E-BP1 functions as a translational repressor by binding and inhibiting 
eIF4E, an initiation factor at the mRNA 5´-cap. Phosphorylation of 4E-BP1 by mTORC1 
enables its dissociation from eIF4E and thus initiates translation. mTORC1 mediated 
phosphorylation of S6K1 enables its binding to or the phosphorylation of multiple proteins 
like ribosomal protein S6 (S6) (Ruvinsky et al. 2005), eIF4B (Holz et al. 2005), eEF2K 
(Wang et al. 2001), CBP80 (Wilson et al. 2000) and SKAR (Ma et al. 2008), which also 
affect translation initiation.  
 
The functions of mTORC2 are less understood than those of mTORC1. Growth factors, 
but not nutrients, cause a response mainly through phosphorylation and activation of 
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AGC kinases such as AKT (or protein kinase B), protein kinase C (PKC) and serum- and 
glucocorticoid-regulated kinase (SGK). SGK and PKC are involved in cell survival, cell 
cycle progression and anabolism. mTORC2 phosphorylation of AKT primes it for further 
phosphorylation by PDK1 (Sarbassov et al. 2005; Garcia-Martinez and Alessi 2008; 
Ikenoue et al. 2008). The two mTOR complexes exhibit complicated cross-talk reactions 
between each other. mTORC1 affects upstream players of the PI3K-AKT signalling 
pathway (IRS-1 and Grb10) thus negatively regulating both mTOR complexes (Um et al. 
2004; Hsu et al. 2011). Recent studies also identified a direct negative regulation of 
mTORC1 towards mTORC2 via phosphorylation of SIN1 through S6K. SIN1 is part of the 
mTORC2 complex and important for its stability and its phosphorylation by S6K leads to 
the dissociation of the complex (Liu et al. 2013).  
 
The major regulatory inputs for mTORC1 are nutrients, growth factors, energy and 
stress. The binding of growth factors and mitogens to cognate receptors activates 
different pathways like the PI3K-AKT, Ras-Raf-MEK-ERK and Wnt-GSK3β axis (Manning 
et al. 2002). In these pathways, the TSC1/TSC2 complex takes up a key position in the 
regulation of mTOR (see also Figure 1.3) (Tee et al. 2002). TSC2 contains a GTPase 
activating protein (GAP) domain that converts RHEB (GTPase Ras homologue enriched 
in brain), an essential activator of mTORC1, from its active GTP-bound into an inactive 
GDP-bound state (Saucedo et al. 2003; Zhang et al. 2003). The phosphorylation of 
TSC2, also known as tuberin, by AKT, ERK or RSK inhibits its GAP function, thus 
promoting mTORC1 signalling (Inoki et al. 2002; Roux et al. 2004; Ma et al. 2005). Wnt 
signalling inhibits GSK3β that acts as a negative regulator of the mTORC1 pathway by 
phosphorylating and activating tuberin (Inoki et al. 2006). Tuberin also plays a key role in 
energy- and stress-regulated mTORC1 signalling. Alterations of cellular energy levels are 
sensed by AMPK, which once it is activated phosphorylates tuberin and stimulates its 
GAP activity towards RHEB, and suppression of mTORC1 activity (Inoki et al. 2003). 
Furthermore, AMPK phosphorylates RAPTOR and allows the binding of 14-3-3 proteins, 
enabling the inhibition of mTORC1 through allosteric mechanisms (Gwinn et al. 2008). 
Oxygen stress induces the expression of the REDD1 (regulated in development and 
DNA damage response 1) gene via HIF1α. REDD1 promotes the release of tuberin from 
the inhibitory 14-3-3 proteins, enabling the formation of TSC1/TSC2 complex (Brugarolas 
et al. 2004; DeYoung et al. 2008). REDD1 takes up a special role in the mTOR pathway 
as it is part of a negative feedback loop. Thereby, HIF1α expression is mTORC1 
regulated and high levels of HIF1α in turn transcribe REDD1 which inhibits mTORC1 
(Hudson et al. 2002). DNA damage suppresses mTORC1 activity through a p53-
dependent activation of AMPK, whereas the overexpression of the p53 targets sestrin 1 
24 
 
and sestrin 2 activate AMPK (Budanov and Karin 2008). A detailed scheme is described 
in Figure 1.3. Considering the multitude of regulation possibilities of the TSC1/TSC2 
complex it is not surprising that a mutation of those two proteins is the cause of the 
familial cancer syndrome TSC. Patients with this disease suffer from benign tumours 
called hamartomas that occur in the kidney, heart, brain, lung and skin (Orlova and Crino 
2010). As mTOR occupies a key position in the regulation of cell growth and proliferation 
we tried to investigate its role in cells deficient for Vhl that undergo senescence. 
 
 
 
 
 
Figure 1.3: Pathways affecting mTOR signalling.  
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1.2.4.2 LKB1-AMPK signalling axis 
1.2.4.2.1 Serine-threonine kinase liver kinase B1 
The serine-threonine kinase liver kinase B1 (LKB1 or STK11) is a tumour suppressor 
gene originally identified as the gene responsible for the inherited Peutz-Jeghers 
syndrome (Hemminki et al. 1998). This rare disease has a predisposition to benign 
intestinal hamartomatous polyps and malignancies in the gastrointestinal tract, breast, 
testis and ovary (Giardiello et al. 1987). Other clinical hallmarks are a melanin 
pigmentation of the skin and mucous membranes (Hemminki 1999). In non-small cell 
lung carcinoma STK11 is one of the most commonly mutated genes (15-35%) (Sanchez-
Cespedes et al. 2002), as well as in cervical carcinomas where it is somatically mutated 
in up to 20% of cases (Wingo et al. 2009). A recent study identified LKB1 as a tumour 
suppressor in sporadic cases of ccRCC whereas its underexpression seems to be 
important for cancer progression (Duivenvoorden et al. 2013).  
 
There are two isoforms of LKB1 generated by alternate splicing with different C-terminal 
sequences, with the shorter version LKB1S lacking phosphorylation (Ser431) and 
farnesylation (Cys433) sites. Both forms are widely expressed but LKB1S is 
predominantly expressed in testis where its loss causes infertility (Towler et al. 2008; 
Denison et al. 2009). The LKB1 protein forms a complex with STE20-related adapter 
(STRAD) and scaffolding mouse 25 (MO25) proteins that are important for its activation 
and translocation from the nucleus to the cytoplasm (Baas et al. 2003; Boudeau et al. 
2003). LKB1 is the key upstream activator of the AMP-activated protein kinase (AMPK) 
family including AMPKα, NUAK and MARK (Lizcano et al. 2004) and is therefore involved 
in controlling cell growth, energy metabolism and cell polarity (Shackelford and Shaw 
2009).  
 
1.2.4.2.2 AMP-activated protein kinase 
The main energy sensor in cells is the AMP-activated protein kinase (AMPK). During 
stress situations such as nutrient and oxygen starvation it works as a key regulator of 
cellular energy metabolism by sensing increases in AMP/ATP and AMP/ADP ratios or 
elevated levels of Ca2+ (Salt et al. 1998; Marsin et al. 2000). However, other signals such 
as reactive oxygen species (ROS) also activate AMPK (Zmijewski et al. 2010). AMPK is 
a heterotrimeric kinase complex composed of a catalytic subunit (AMPKα) and two 
regulatory subunits (AMPKβ and AMPKγ). The subunits α and β are both encoded by 
two different genes (α1 or α2 and β1 or β2), whereas the γ-subunit has three responsible 
genes (γ1, γ2 or γ3) (Stapleton et al. 1996; Woods et al. 1996). The α-subunit contains a 
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serine/threonine kinase domain with a conserved threonine residue (Thr172), which 
upstream kinases are able to phosphorylate. This phosphorylation increases the activity 
of AMPK by several hundred folds (Suter et al. 2006). The γ-subunit contains four 
different binding sites for AMP, ADP and ATP, which regulate the status of AMPK (Xiao 
et al. 2007). Binding of AMP or ADP to the γ-subunit promotes phosphorylation and 
inhibits dephosphorylation of the Thr172 residue but only AMP is able to allosterically 
activate AMPK (Davies et al. 1995; Hawley et al. 1995; Xiao et al. 2011). However, ATP 
binds to the same sites in the γ-subunit as AMP and ADP do, antagonising all of their 
effects (Davies et al. 1995). The two major kinases phosphorylating AMPK are the LKB1-
STRAD-MO25 complex, responsible for the above-described way of activation (Hawley 
et al. 2003; Woods et al. 2003; Shaw et al. 2004), as well as calcium/calmodulin-
dependent protein kinase kinase-β (CaMKKβ) that is activated by elevated calcium levels 
in the absence of increased AMP levels (Hawley et al. 2005; Hurley et al. 2005; Woods 
et al. 2005).  
 
To maintain the energy balance in cells, on the one hand AMPK activates catabolic 
processes to generate ATP and on the other hand inhibits energy-consuming pathways. 
Therefore, it is involved in regulation of glucose, protein and lipid metabolism, as well as 
in mitochondrial biogenesis and autophagy. Through this, AMPK promotes the uptake of 
glucose (through transporter Glut1 and Glut4) (Kurth-Kraczek et al. 1999; Barnes et al. 
2002) and its catabolism via glycolysis (PFKFB3) (Marsin et al. 2002) including the 
uptake of fatty acids into the mitochondria and their breakdown in β-oxidation (ACC2) 
(Merrill et al. 1997) and inhibits fatty acid synthesis (ACC1) (Hardie and Pan 2002). In 
addition to promotion of catabolic pathways, AMPK inhibits anabolic processes such as 
protein synthesis. AMPK directly phosphorylates and activates TSC2 that in complex with 
TSC1 serves as an inhibitor of the mTORC1 complex, a key regulator of protein 
metabolism. TSC2 functions as a GTPase-activator protein that inhibits RHEB, an 
upstream activator of mTORC1 (Inoki et al. 2003). Furthermore, RAPTOR is 
phosphorylated by AMPK and 14-3-3 binding is induced that is responsible for mTORC1 
inhibition (Gwinn et al. 2008). Together with mTORC1, AMPK also coordinates the 
regulation of autophagy/mitophagy. mTORC1 operates as a suppressor of ULK1 and 
ULK2 (Unc-51-like kinase 1 and 2) activity during nutrient-rich conditions whereas AMPK 
phosphorylates and activates these two proteins in response to low nutrient availability 
and inhibits mTORC1 directly as mentioned above and thus promotes autophagy (Chan 
2009; Egan et al. 2010). 
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Additionally, AMPK seems to be involved in the regulation of the cell cycle. Jones and 
colleagues revealed that AMPK activation due to glucose deprivation induces the 
phosphorylation of p53 at Ser15 and an upregulation of its target gene p21, both involved 
in regulation of the cell cycle (Jones et al. 2005). In tuberin-null cells with elevated AMPK 
signalling the cyclin-dependent kinase inhibitor p27Kip1 is phosphorylated by AMPK. This 
promotes its stabilisation as well as its sequestration to the cytoplasm and exhibits 
elevated levels of Cdk2 activity (Short et al. 2008; Short et al. 2010). The role of AMPK-
mediated p27Kip1 stabilisation in cell cycle is still not fully understood but phosphorylated 
p27Kip1 by AMPK can also inhibit apoptosis and support autophagy (Liang et al. 2007). In 
this thesis we could show that the senescence phenotype of Vhl-deficient cells was 
accompanied by decreased levels of ATP. As AMPK is the energy sensor in cells we 
tried to investigate the role of AMPK in cells deficient for Vhl. 
 
1.3 Cell cycle regulation and its link to cancer 
Primary as well as transformed MEFs with a deletion of Vhl show signs of premature 
senescence or proliferation arrest, respectively (Mack et al. 2005; Young et al. 2008; 
Welford et al. 2010), possibly initiated by oxidative stress (Welford et al. 2010). Mack and 
colleagues showed that mRNA expression and protein levels of p21Cip1 and p27Kip1 were 
elevated in Vhl negative immortalised MEFs and fibrosarcomas caused through 
stabilised HIF activity, which suppressed C-MYC transcriptional repression towards p21 
and p27 (Mack et al. 2005). Another study claimed that immortalized Vhl MEFs exhibited 
decreased levels of Skp2 that caused stabilisation of p27Kip1 and resulted in hypo-
phosphorylated Rb in a p53- and Hif-independent manner (Young et al. 2008). The Vhl 
induced senescence seems to be dependent on functional cell cycle and senescence 
pathway regulators pRb (Young et al. 2008) or p53 (Welford et al. 2010). In terms of the 
central role pRb and p53 have in regulating cell cycle and senescence, these data 
provide strong evidence that during cancer progression, loss of Vhl activates a barrier for 
proliferation, which presumably has to be overcome by additional mutations in cellular 
checkpoints to facilitate tumour formation. Another interesting link between pVHL and cell 
cycle regulation is its gate keeping function in terms of contact inhibition. In renal 
epithelial cells pVHL is essential for the generation and maintenance of contact inhibition 
of cell growth (Baba et al. 2001). The loss of VHL in RCC cell lines causes elevated 
cyclin D1 expression levels at high cell densities through stabilised HIF signalling (Bindra 
et al. 2002; Baba et al. 2003). Interestingly, in 40% of cases of sporadic ccRCC 
components of senescence and cell cycle checkpoints have genetic alterations including 
mutations or copy number deletions in TP53, ATM, CHEK2, MDM2, CDKN2A, E2F3 or 
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RB1 or copy number gains in MYC (Sato et al. 2013). These results strongly support the 
idea from in vitro studies that the loss of function of VHL cooperates with impaired cell 
cycle machinery thus leading to ccRCC development. With the generation of a mouse 
model we investigated the interaction between the two tumour suppressor genes Vhl and 
Rb1. 
 
1.3.1 Cell cycle 
Alterations in cell cycle genes are important events for cancer progression. The cell cycle 
is defined as the replication of DNA and the division of cells to yield two daughter cells. It 
is divided into mitosis (M) and interphase, while the actual cell division takes part in the M 
phase. The interphase consists of G1, S, and G2 phases. DNA replication occurs during 
S phase and is separated from the M phase by two gap phases (G1 and G2) where cells 
are enabled to repair DNA damage and replication errors. In G1, cells prepare for DNA 
synthesis whereas in G2 they prepare for mitosis. Cells that have ceased proliferation 
enter a silent phase called G0. The cyclin-dependent kinases (Cdk) are the key 
regulators of the transition between the different cell cycle phases (Malumbres et al. 
2009). The Cdks are heterodimeric protein kinases containing a serine/threonine-specific 
catalytic core (Cdk) and regulatory binding partners called cyclins. Progression through 
the cell cycle requires different Cdk/cyclin complexes. For entering G1, mitogenic signals 
via PI3K-AKT and Ras-Raf-MEK-ERK pathways induce cyclin D (D1, D2, D3) 
expression, allowing the Cdk4/6-cyclin D complex to assemble (Sherr and Roberts 
1999). The most recognized function of this complex is the initial phosphorylation and 
thus inactivation of RB family members. Inactive RB releases E2F and thus allows the 
transcription of cyclin E that in turn is, together with Cdk2, required for progression from 
G1 to S phase, causing unwinding of the double helix and DNA replication (Kelly and 
Brown 2000; Prasanth et al. 2004). Cdk2/cyclin E enforces RB phosphorylation and the 
created feedback-loop enables an irreversible G1/S transition. At the end of the S phase, 
when Cdk2 is no longer bound to cyclin E, it associates with cyclin A and allows 
completion and exit from this phase. At the same time, Cdk1 binds cyclin A that is 
replaced by cyclin B during transition of G2 to M (Sherr and Roberts 1999). The kinase 
activity of the Cdk/cyclin complex is regulated by cell cycle inhibitory proteins called Cdk 
inhibitors (CKI). They are divided in two subgroups, the INK4 and Cip/Kip family (Sherr 
and Roberts 1995). The INK4 family consists of p16INK4a (Cdkn2a), p15INK4b (Cdkn2b), 
p18INK4c (Cdkn2c) and p14INK4d (Cdkn2d). They bind specifically to Cdk4 and Cdk6 
proteins thus preventing cyclin D association (Carnero and Hannon 1998). The Cip/Kip 
family includes p21Cip1 (Cdkn1a), p27Kip1 (Cdkn1b) and p57Kip2 (Cdkn1c) and inactivates 
cyclin D-/E-/A- and B-dependent kinase complexes by binding to these complexes. 
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Internal as well as external signals regulate the CKIs. For example p21Cip1 is 
transcriptionally controlled by p53 whereas the expression and activation of p15INK4b and 
p27Kip1 is regulated by TGF-β (Vermeulen et al. 2003). During the cell cycle, there are 
several DNA damage and spindle checkpoints, to ensure an orderly process of events 
(Hartwell and Weinert 1989). The DNA damage checkpoints take place during transition 
of G1-S and G2-M phase. DNA damage occurring in G1 phase is sensed by pathways 
that lead to p53 activation and target genes like p21 are transcribed. The cell cycle arrest 
at the G2 checkpoint can be initiated with or without p53. The Cdk kinase activity is, 
beside cyclins and CKIs, also controlled by phosphorylation or dephosphorylation events, 
protein folding and subcellular localisation (Sherr and Roberts 1999).  
 
1.3.2 Senescence 
Apoptosis and senescence can be teleologically envisaged as internal protection 
mechanisms that cells use to prevent uncontrolled cell proliferation. During cellular 
senescence, cells irreversibly arrest proliferation but are still metabolically active. The 
triggers of senescence are telomere shortening, DNA damage, chromatin remodelling 
and strong mitogenic signals (Campisi 2001). p53 and pRB are important tumour 
suppressors that, due to diverse stimuli, maintain pathways leading to growth arrest. 
These two proteins are further described in 1.3.3 and 1.3.4 respectively. The inactivation 
of p53 in primary MEFs is likewise sufficient for accelerated growth due to the prevention 
of senescence (Dirac and Bernards 2003). During senescence, E2F1, oncogenic Ras 
and DNA damage induce p14ARF (p19ARF in mouse) that sequesters MDM2 (mouse 
double minute 2 homolog), a protein involved in degradation of p53, thus activating p53 
(Bringold and Serrano 2000). pRB only exists in its hypophosphorylated and thus active 
form in senescent cells. The Cdks that phosphorylate and inactivate pRB during cell 
cycle are mainly inhibited by p16INK4a but also p21Cip1 and in some cases by p27Kip. These 
genes are highly expressed in senescent cells and induced by oncogenes and other 
stress stimuli (Serrano et al. 1993; Campisi 2001; Lowe and Sherr 2003). The two 
different senescence pathways interact with each other at multiple levels. The above 
mentioned Cdk inhibitor and thus pRB activator p21Cip1 for example is a direct target 
gene of p53. Furthermore, pRB prevents the degradation of p53 by binding to and 
inactivation of MDM2 (Campisi 2001). 
 
1.3.3 Retinoblastoma protein 
The retinoblastoma protein family consists of the three members RB1, RBL1 (p107) and 
RBL2 (p130). As these family members are structurally and functionally similar they have 
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overlapping and compensatory and in some contexts individual functions (Claudio et al. 
2002). These tumour suppressors are, as already mentioned, involved in cell cycle 
regulation where they inhibit E2F family members in the transition of G1 to S phase by 
binding to them. E2F1, E2F2 and E2F3a, which act as transcriptional activators, are 
under the direct control of RB1 whereas E2F4 and E2F5, transcriptional repressors, are 
bound by RBL1 and RBL2 (Sun et al. 2007). During cell cycle progression, the function of 
RB is regulated by its phosphorylation status influenced by different Cdk/cyclin 
complexes (Buchkovich et al. 1989). Beside cell cycle modulation, RB is also involved in 
the induction and maintenance of cellular senescence, the regulation of apoptosis, 
chromosomal stability, cellular differentiation and angiogenesis (Burkhart and Sage 
2008). Its special role in senescence is described in section 1.3.2. Interestingly, a recent 
study revealed a new role for the Rb pathway in glutamine metabolism having a direct 
metabolic control of ATP and macromolecular production. The loss of the complete Rb 
family (Rb1, Rbl1 and Rbl2) enhanced glutamine uptake via E2F3 and the upregulation 
of the expression of the glutamine transporter ASCT2, increased Gls1 activity and 
increased glutathione synthesis (Reynolds et al. 2014). Taken together, Rb1 is important 
for cell cycle regulation and could be involved in cell metabolism. Therefore, we 
examined the effects of Rb1 loss in Vhl-deficient MEFs which display a senescence 
phenotype. 
 
1.3.4 p53 
The tumour suppressor TP53, encoding p53, is the most frequently mutated gene in an 
enormous variety of different types of cancer (Levine and Oren 2009). p53 has a 
diversified range of tasks and thus occupies an important position in stress response 
networks. It is induced by different stress stimuli like DNA damage, hypoxia and oxygen 
stress. The induction of p53 facilitates DNA repair during the cell cycle and activates 
apoptotic or senescence responses, all being major mechanisms for tumour suppression 
(Levine and Oren 2009). Furthermore, recent findings suggest an important function of 
p53 in the regulation of the metabolic homeostasis in cells. Dependent on nutrient and 
oxygen availability, p53 regulates a complex network of different metabolic pathways like 
glycolysis (GLUT1, HK, PGM), oxidative phosphorylation (SCO2), glutaminolysis (GLS2), 
fatty acid oxidation (GAMT), nucleotide biosynthesis (G6PD), mitochondrial integrity, 
antioxidant response, insulin sensitivity, mTOR signalling and autophagy (LC3) 
(Maddocks and Vousden 2011). Thereby, p53 acts as a transcription factor and alters the 
expression of hundreds of genes (Menendez et al. 2009). On the other hand p53 can 
also operate as a transcriptional repressor (Ginsberg et al. 1991). In unstressed cells, 
p53 is maintained at low levels by MDM2 that acts as an E3 ligase supporting the 
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degradation of p53 (Freedman et al. 1999). As MDM2 is also a transcriptional target of 
p53 the increased activation of p53 drives the expression of its own negative regulator 
and creates a negative feedback loop (Wu et al. 1993). Upon DNA damage, the tumour 
suppressor pVHL directly acts as a positive regulator of p53. It associates with p53, 
leading to its stabilisation and blocking MDM2 mediated ubiquitination of p53 and its 
export from the nucleus (Roe et al. 2006). Besides pRB, p53 is another crucial cell cycle 
and senescence regulator in cells. One aim of this thesis is to understand the effects of 
combined Vhl and p53 loss on the cell metabolism and their contribution to 
transformation. 
 
1.4 Aims 
This thesis has the following aims: 
1. Analysis of metabolic processes, especially oxygen and nutrient sensing pathways 
that are dysregulated after loss of pVHL function and their implication for tumour 
formation. 
2. Examination of the effect of combined loss of Vhl and Trp53 or Rb1 on cellular 
senescence and cell metabolism following loss of pVHL function.  
3. Generation of a mouse model with inducible kidney epithelial cell-specific combined 
deletion of Vhl and Rb1 to study their cooperative effects in ccRCC development. 
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2 Materials and Methods 
2.1 Materials 
2.1.1  General Chemicals  
Reagent Supplier 
30% Acrylamide/Bisacrylamide Solution Bio-Rad 
Acetic acid (glacial) Merck 
Acetone Sigma-Aldrich 
Agarose, D1 low EEO Conda 
Agarose, low melting point Sigma-Aldrich 
 Albumin from bovine serum Sigma-Aldrich 
Ammonium carbonate Sigma-Aldrich 
Ammonium chloride Fluka 
Boric acid Sigma-Aldrich 
Bovine serum albumin (BSA) Invitrogen 
Bromophenol blue Sigma-Aldrich 
Citric acid monohydrate Sigma-Aldrich 
Crystal violet Sigma-Aldrich 
Dimethylsulfoxide (DMSO) Sigma-Aldrich 
di-sodium hydrogen orthophosphate (Na2HPO4) Sigma-Aldrich 
Dithiothreitol (DTT) Sigma-Aldrich 
Entellan Merck 
Eosin 1% (aqueous) BioSystems 
Ethanol AUL 
Ethidium bromide  Sigma-Aldrich 
Ethylenediamine tetra-acetic acid (EDTA) disodium salt 
dihydrate 
Sigma-Aldrich 
Formalin 10%, neutral buffered Sigma-Aldrich 
Glycerol Sigma-Aldrich 
Haematoxylin (Mayer’s) J.T.Baker 
Hydrochloric acid, 32% Sigma-Aldrich 
Hydrogen peroxide Sigma-Aldrich 
Isopropanol AUL 
L-glutamine [5-C14]  Hartmann Analytic 
Magnesium chloride Sigma-Aldrich 
Magnesium sulfate Sigma-Aldrich 
Methanol AUL 
Mowiol  Sigma-Aldrich 
N,N,N’,N’-Tetramethylethylenediamine (TEMED) Bio-Rad 
N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic acid 
(HEPES) 
Sigma-Aldrich 
NP-40 Sigma-Aldrich 
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Reagent Supplier 
Paraformaldehyde Sigma-Aldrich 
p-coumaric acid Sigma-Aldrich 
Phenyl-methyl-sulphonyl-fluoride (PMSF) Sigma-Aldrich 
Potassium acetate Sigma-Aldrich 
Potassium chloride Sigma-Aldrich 
Propidium iodide (PI) Sigma-Aldrich 
Protease inhibitor cocktail Sigma-Aldrich 
Protein assay Dye Reagent Bio-Rad 
Safflower oil Migros 
Sodium acetate Sigma-Aldrich 
Sodium azide Sigma-Aldrich 
Sodium chloride Sigma-Aldrich 
Sodium deoxycholate Sigma-Aldrich 
Sodium dihydrogen orthophosphate (NaH2PO4) Sigma-Aldrich 
Sodium Dodecyl Sulfate (SDS) Sigma-Aldrich 
Sodium hydroxide Sigma-Aldrich 
Sulforhodamine B sodium salt (SRB) Sigma-Aldrich 
SYBR FAST Universal 2X qPCR Master Mix KapaBiosystems 
SYBR Green JumpStart Taq ReadyMix Sigma-Aldrich 
Trichloroacetic acid Sigma-Aldrich 
Tris(hydroxymethyl)aminomethane (Tris base) Sigma-Aldrich 
Tris(hydroxymethyl)aminomethane hydrochloride (Tris HCl) Sigma-Aldrich 
Tri-Sodium citrate Sigma-Aldrich 
Triton X-100 Sigma-Aldrich 
Tween-20 Sigma-Aldrich 
Xylene Thommen-Furler AG 
 
2.1.2  Drugs & tissue culture reagents 
Reagent  Supplier 
2−Mercaptoethanol Bio-Rad 
2´,7´-dichlorodihydrofluorescein diacetate Invitrogen 
3,3,5 Triiodothyronine (T3) Sigma-Aldrich 
Acridine Orange 10-nonyl bromide Sigma-Aldrich 
Ampicillin Sigma-Aldrich 
Apo-Transferrin (TF), human Sigma-Aldrich 
Calcium chloride Sigma-Aldrich 
Collagenase Type II Gibco 
Cycloheximid Sigma-Aldrich 
D-glucose Sigma-Aldrich 
DMEM without L-methionine, L-cystine Sigma-Aldrich 
DMEM/F12 Sigma-Aldrich 
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Reagent  Supplier 
Dulbecco’s Modified Eagle Medium (DMEM) Sigma-Aldrich 
Epidermal Growth factor (EGF), murine PeproTech 
Fetal Calf Serum (FCS) Biochrome AG 
HBSS Gibco 
Hepatocyte Growth factor (HGF) PeproTech 
HEPES 1M Sigma-Aldrich 
Hydrocortisone (HC) Sigma-Aldrich 
Insulin, human Sigma-Aldrich 
Kanamycin Sigma-Aldrich 
L-Glutamine Sigma-Aldrich 
Luria Bertani Bouillon medium Sigma-Aldrich 
Met-[S35]-label (SCIS-103) Hartmann Analytics 
Penicillin/Streptomycin PAA 
Phosphate Buffered Saline (PBS) Biochrome Ag 
Polybrene (Hexadimethrine Bromide) Sigma-Aldrich 
Prostagladin E1 (PGE1) Sigma-Aldrich 
Puromycin InvivoGen 
S.O.C. medium Invitrogene 
Sodium bicarbonate Sigma-Aldrich 
Sodium bicarbonate Sigma-Aldrich 
Tamoxifen Sigma-Aldrich 
Trypsin EDTA Gibco 
Trypsin inhibitor, soybean Gibco 
 
2.1.3  Kits 
Name Supplier 
ABC Kit (PK6100) Vectorstain 
Avidin/Biotin Blocking Kit (SP 2001) VectorLaboratories 
CellTiter-Glo Luminescent Cell Viability Assay Promega 
CSA detection kit Dako 
DAB Substrate Kit (SK-4100) VectorLaboratories 
GenElute Mammalian Genomic DNA Miniprep Kit Sigma-Aldrich 
Glucose assay Kit II Biovision 
Lactate assay Kit II Biovision 
NucleoBond Xtra Midi Macherey-Nagel 
NucleoSpin RNA kit Macherey-Nagel 
Ready-To-Go You-Prime First-Strand Beads GE Healthcare 
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2.1.4 Antibodies 
Name Vendor Order 
number 
Source Dilution Application 
β-Actin (AC-74) Sigma-Aldrich A2228 Mouse 1:1000 WB 
Acetyl-CoA-
Carboxylase  
Cell Signaling 
Technologies 
3662 Rabbit 1:1000 WB 
Phospho-Ser79-
Acetyl-CoA- 
Carboxylase 
Cell Signaling 
Technologies 
3661 
 
Rabbit 1:1000 WB 
AMPKα (F6) Cell Signaling 
Technologies 
2793 
 
Mouse 1:1000 WB 
AMPKα1 (Y365) Abcam ab32047 Rabbit 1:1000 WB 
AMPKα2 (Y365) Abcam ab3760  Rabbit 1:1000 WB 
Phospho-
Thr172-AMPKα  
Cell Signaling 
Technologies 
2535 
 
Rabbit 1:1000 WB 
4E-BP1 (53H11) Cell Signaling 
Technologies 
9644 Rabbit 1:1000 WB 
Phospho-
Thr37/46-4E-
BP1 
Cell Signaling 
Technologies 
2855 Rabbit 1:1000 WB 
GLS2 Novus 
Biologicals 
NBP1-54773 Rabbit 1:500 WB 
GLS2 R471 Abcam AP6650b  Rabbit 1:500 WB 
Hamartin  Cell Signaling 
Technologies 
4906 Rabbit 1:1000 WB 
HIF1α (H1α67) Novus 
Biotechnologies 
NB-100-105 Mouse 1:20000 IHC 
HIF1α Novus 
Biotechnologies 
NB-100-479 Rabbit 1:1000 WB 
HRP anti-mouse ThermoScientific 31430 Goat 1:1000 IHC 
LDH-A (N-14) Santa Cruz 
Biotechnology 
Sc-27230 
 
Goat 1:1000 WB 
LKB1 (D60C5) 
 
Cell Signaling 
Technologies 
3047 Rabbit 1:1000 WB 
p53 Leica 
Microsystems 
NCL-p53-
CM5p 
Rabbit 1:1000 WB 
Phospho-Ser15-
p53 
Cell Signaling 
Technologies 
9284 
 
Rabbit 1:500 WB 
PDK-1 Enzo Life 
Sciences 
ADI-KAP-
PK112-D 
Rabbit 1:1000 WB 
Retinoblastoma 
Protein (G3-245) 
BD Biosciences 554136 Mouse 1:1000 
1:7000 
WB 
IHC 
S6 ribosomal 
protein 
Cell Signaling 
Technologies 
2217 
 
Rabbit 1:1000 WB 
Phospho-
Ser240/244-
ribosomal S6 
protein 
Cell Signaling 
Technologies 
2215 
 
Rabbit 1:1000 WB 
p70 S6 kinase 
(49D7) 
Cell Signaling 
Technologies 
2708 Rabbit 1:1000 WB 
Phospho-
Thr389-p70 S6 
kinase (1A5) 
Cell Signaling 
Technologies 
9206 Rabbit 1:1000 WB 
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Name Vendor Order 
number 
Source Dilution Application 
Tuberin (D57A9) Cell Signaling 
Technologies 
3990 Rabbit 1:1000 WB 
VHL (FL-181) Santa Cruz 
Biotechnologies 
Sc-5575 Rabbit 1:100 WB 
 
2.1.5 Oligonucleotide sequences 
Name Sequence Application 
Control band Cre 
fwd 
ATA ATG CCT TTC CTC AGT AAA CCA G Genotyping 
Control band Cre 
rew 
GGA TCC CAT TAC AGA TGG TTG TG Genotyping 
Ksp.Cre1.3 fwd AGG TTC GTG CAC TCA TGG A Genotyping 
Ksp.Cre1.3 rev TCG ACC AGT TTA GTT ACC C Genotyping 
Rb1 fwd GGC GTG TGC CAT CAA TG Genotyping 
Rb1 rev AAC TCA AGG GAG ACC TG  Genotyping 
Trp53 fwd GCC CTC TCT TAT CGC CAG AT Genotyping 
Trp53 rev GCT TAT GGG CTT CTC CAA ACT Genotyping 
Vhl fwd GGA GTA GGA TAA GTC AGC TG Genotyping 
Vhl rev GTA CAC CTG AGA GCG GCT TC Genotyping 
Aco1 fwd ACT CAA GAT ACG GAC GCT TAC C RT-qPCR 
Aco1 rev GTT GCA TGA CAT TCC AAT TCA GG  RT-qPCR 
Aco2 fwd ATC GAG CGG GGA AAG ACA TAC  RT-qPCR 
Aco2 rev TGA TGG TAC AGC CAC CTT AGG  RT-qPCR 
Asct2 fwd CAT CAA CGA CTC TGT TGT AGA CC  RT-qPCR 
Asct2 rev CGC TGG ATA CAG GAT TGC GG  RT-qPCR 
Gls1 fwd AGT TGT CCC CAA CGT CAT GGG C  RT-qPCR 
Gls1 rev AGT CCA ATG GTC CAA AGG AAT GC  RT-qPCR 
Gls2 A fwd GCA CTC GGA TCA TGA CGC CTC AC  RT-qPCR 
Gls2 A rev TTG GAC CAT GCG CTG CAT CTT G  RT-qPCR 
Gls2 B fwd CGT CCG GTA CTA CCT CGG T  RT-qPCR 
Gls2 B rev TGT CCC TCT GCA ATA GTG TAG AA RT-qPCR 
Gls2 C fwd CAG AGG GAC AGG AGC GTA TC RT-qPCR 
Gls2 C rev TTC TTT CGG AAT GCC TGA GTC RT-qPCR 
Gls2 D fwd TCA GGC ATT CCG AAA GAA GTT T RT-qPCR 
Gls2 D rev CAG AAG GGG ATC TTC GTG TGG RT-qPCR 
Glud1 fwd CCC AAC TTC TTC AAG ATG GTG G RT-qPCR 
Glud1 rev AGA GGC TCA ACA CAT GGT TGC  RT-qPCR 
Glut1 fwd GCT TAT GGG CTT CTC CAA ACT RT-qPCR 
Glut1 rev GGT GAC ACC TCT CCC ACA TAC RT-qPCR 
Got1 fwd GCG CCT CCA TCA GTC TTT G RT-qPCR 
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Name Sequence Application 
Got1 rev ATT CAT CTG TGC GGT ACG CTC RT-qPCR 
Got2 fwd GGA CCT CCA GAT CCC ATC CT RT-qPCR 
Got2 rev GGT TTT CCG TTA TCA TCC CGG TA RT-qPCR 
Hif1a fwd TGCTCATCAGTTGCCACTTC RT-qPCR 
Hif1a rev CCTCATGGTCACATGGATGA RT-qPCR 
Hif2a fwd CTG ATG GCC AGG CGC ATG ATG RT-qPCR 
Hif2a rev CTG ATG GCC AGG CGC ATG ATG RT-qPCR 
Idh1 fwd ATG CAA GGA GAT GAA ATG ACA CG RT-qPCR 
Idh1 rev GCA TCA CGA TTC TCT ATG CCT AA  RT-qPCR 
Idh2 fwd GGA GAA GCC GGT AGT GGA GAT RT-qPCR 
Idh2 rev GGT CTG GTC ACG GTT TGG AA RT-qPCR 
Ldha fwd TGG CTT TCC CAA AAA CCG AGT  RT-qPCR 
Ldha rev CCA TCA GGT AAC GGA ACC GC RT-qPCR 
Lga fwd GCC AGA TGG TTC AAA GAG GAG G RT-qPCR 
Lga rev GTG GTG AAC TTG TGG ATA GGG RT-qPCR 
Mdm2 fwd AGG AGA TGT GTT TGG AGT CCC RT-qPCR 
Mdm2 rev CTC AGC GAT GTG CCA GAG TC RT-qPCR 
p21 fwd CCT GGT GAT GTC CGA CCT G RT-qPCR 
p21 rev CCA TGA GCG CAT CGC AAT C RT-qPCR 
Pdk1 fwd AGG ATC AGA AAC CGG CAC AAT RT-qPCR 
Pdk1 rev GTG CTG GTT GAG TAG CAT TCT A RT-qPCR 
Pfkfb3 fwd CAA CTC CCC AAC CGT GAT TGT  RT-qPCR 
Pfkfb3 rev TGA GGT AGC GAG TCA GCT TCT RT-qPCR 
Pgk1 fwd TGG AGC CAA CTC CGT TGT C RT-qPCR 
Pgk1 rev CAG GCA TTC TCG ACT TCT GGG RT-qPCR 
Prkaa1 fwd TCG GCA CCT TCG GGA AA  RT-qPCR 
Prkaa1 rev GTT GAG TAT CTT CAC AGC CAC TTT 
ATG T  
RT-qPCR 
Prkaa2 fwd CGC CTC TCA TCG CAG ACA RT-qPCR 
Prkaa2 rev CTT GGG CTT CGT TGT GTT GA RT-qPCR 
Rb1 fwd TGC ATC TTT ATC GCA GCA GTT  RT-qPCR 
Rb1 rev GTT CAC ACG TCC GTT CTA ATT TG RT-qPCR 
S12 fwd GAA GCT GCC AAA GCC TTA GA  RT-qPCR 
S12 rev AAC TGC AAC CAA CCA CCT TC RT-qPCR 
Stk11 fwd TTG GGC CTT TTC TCC GAG G  RT-qPCR 
Stk11 rev CAG GTC CCC CAT CAG GTA CT RT-qPCR 
Tigar fwd GCC TGG AGG AGA GAC AGT TG  RT-qPCR 
Tigar rev TCC AAC AGG GAA AAC CTC TG  RT-qPCR 
Trp53 fwd GCG TAA ACG CTT CGA GAT GTT RT-qPCR 
Trp53 rev TTT TTA TGG CGG GAA GTA GAC TG RT-qPCR 
Vhl fwd CAG CTA CCG AGG TCA TCT TTG RT-qPCR 
Vhl rev CTG TCC ATC GAC ATT GAG GGA  RT-qPCR 
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2.1.6 Plasmids and lentiviral vectors 
Name Reference Vendor 
pLKO.1-Vhl gift from Krek lab  
pLKO.1-ns 10879 Addgene 
psPAX2 10879 Addgene 
pMD2.G 12259 Addgene 
pLKO.1-Tsc1 NM_022887.3-462s21c1 Sigma-Aldrich 
pLKO.1-Tsc2 NM_011647.2-1874s21c1 Sigma-Aldrich 
pLKO.1-Gls1 NM_001081081.2-983s21c1 Sigma-Aldrich 
pLKO.1-Gls2 NM_001033264.1-2135s1c1 Sigma-Aldrich 
pLKO.1-Stk11 NM_011492.1-1189s1c1 Sigma-Aldrich 
pLKO.1-Stk11 NM_011492.1-783s1c1 Sigma-Aldrich 
pLKO.1-Stk11 NM_011492.1-1585s1c1 Sigma-Aldrich 
pLKO.1-Stk11 NM_011492.1-736s1c1 Sigma-Aldrich 
pLKO.1-Prkaa1 XM_139298.4-1540s1c1 Sigma-Aldrich 
pLKO.1-Prkaa1 XM_139298.4-1396s1c1 Sigma-Aldrich 
Adeno-Cre-GFP Vector Biolabs 1700 
Adeno-GFP Vector Biolabs 1060 
 
2.2 Cell infection 
2.2.1 Bacterial strains and media 
Plasmid DNA was grown in the bacterial strain Mach1-T1R. S.O.B. medium and Luria 
Bertani Bouillon medium was used for growth of bacteria. 
 
2.2.2 Transformation of bacterial cells with plasmid DNA 
The plasmid DNA was added to 100 µl of chemically competent bacteria thawed on ice. 
The DNA/cell mix was incubated on ice for 30 minutes and then heated for 45 seconds at 
42°C without shaking. Afterwards, cells were placed on ice for 2 minutes followed by 
addition of room temperature S.O.C. medium. Cells were incubated at 37°C for 1 hour at 
300 rpm in a shaking incubator. Finally, transformation mix was plated onto pre-warmed 
agar plates containing appropriate antibiotics (100 µg/ml ampicillin or 50 µg/ml 
kanamycin), and incubated at 37°C overnight. 
39 
 
2.2.3 Isolation of plasmid DNA 
For small-scale preparations, 2 ml of an overnight bacterial culture were centrifuged at 
12000 rpm for 5 minutes. DNA was isolated using GenElute Mammalian Genomic DNA 
Miniprep Kit according to manufacturer´s protocol. 
 
For large-scale preparations, 200 ml of an overnight bacterial culture were centrifuged at 
4500 rpm for 10 minutes. DNA was isolated using NucleoBond Xtra Midi Kit according to 
the manufacturer's instructions. Following resuspension in TE buffer (Tris 1 mM, EDTA 
10 mM, pH 8), DNA concentration was determined by absorbance at 260 nm.  
 
2.2.4 Adenoviral vectors 
Adenoviruses - Type 5 (dE1/E3) expressing Cre recombinase + GFP (Adeno-Cre) or 
GFP only (Adeno-GFP) was amplified in HEK-293 cells, cultured in DMEM mix (10% 
FCS, 2 mM glutamine, 10 kU/ml penicillin, 10 mg/ml streptomycin). The cells were 
infected with adenoviral stock at 80% confluency. Infection was allowed to proceed until 
80-90% of the cells were rounded up and floating or loosely attached to the tissue culture 
dish. Adenovirus-containing cells were typically harvested 2-3 days after infection and 
centrifuged at 300 rpm for 5 minutes. Cell pellets were resuspended in PBS, frozen in 
liquid nitrogen and thawed again in a 37°C water bath. Freezing and thawing steps were 
repeated twice. Cell lysates were centrifuged at 2900 rpm for 15 minutes at room 
temperature to pellet the cell debris. The supernatant containing viral particles was 
aliquoted and stored at -80°C. 
 
2.2.5 Lentiviral vectors 
Lentiviral vectors were produced using calcium phosphate-mediated transfection of HEK-
293T cells. The cells were maintained in DMEM supplemented with 10% FCS, 2 mM 
glutamine, 10 kU/ml penicillin, 10 mg/ml streptomycin. Transfection was performed when 
50-70% of the plate surface was covered with cells. The medium was replaced with fresh 
DMEM two hours before transfection. The following transfection mix for one 15 cm dish 
was prepared in a 50 ml conical tube: 23 µg transfer vector plasmid, 15 µg packaging 
plasmid: psPAX2, 8 µg amphotropic VSV-G envelope: pMD2.G (Morita et al. 2000), 
660 µl of  0.1x TE, 420 µl of H2O and 375 µl of 1 M CaCl2. 1.5 ml of 2x HEBS (0.05 M 
HEPES, 0.28 M NaCl, pH 7) was added drop wise under agitation. The precipitate was 
left at room temperature for 15 minutes and then added drop wise to the cells. After 
16 hours the medium was aspirated and 14 ml of fresh DMEM was slowly added. The 
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medium containing lentiviral particles was harvested twice every 24 hours. The 
supernatants were cleared by centrifugation at 500 rpm for 5 minutes and filtered using a 
0.45 µm filter unit. Aliquots of lentiviral vectors were stored at -80°C. 
 
2.2.6 Viral Titer determination 
For lentiviral titration 5x104 cells were seeded per 6-well plate the day before infection. 
The next day the virus was diluted in DMEM 1:103, 1:104 and 1:105 and added to the 
cells together with polybrene (4 µg/ml). 24 hours later the viral supernatant was removed 
and the cells were split 1:4 in triplicates on 6-well plates. Two days after infection, 
puromycin selection (2 µg/ml) was performed for 7-10 days. To visualize colony growth, 
the plates were stained with crystal violet (0.3% crystal violet in 70% methanol) at room 
temperature. After 1 hour, cells were washed in tap water and air dried. The viral titer 
corresponds to the number of colonies present at the highest dilution that still contains 
colonies, multiplied by the dilution factor and by two, to account for the twofold increase 
of cells during the transduction period and the 1:4 splitting. 
 
2.2.7 Virus infection of cells 
For lentiviral infection cells were counted and infected with virus of MOI 3. Polybrene 
(4 µg/ml) was supplemented to the media. After 16 hours the media was replaced with 
fresh DMEM. Two days after infection, puromycin selection (2 µg/ml) was performed for 
at least two days before continuing with experiments. 
 
2.3  Cell culture 
2.3.1 Isolation and culturing of mouse embryonic fibroblasts  
Mouse embryonic fibroblasts (MEFs) were isolated from embryos of relevant floxed 
strains at day E13.5. After dissecting away the head, internal organs and spinal cord the 
remaining tissue was minced with a razorblade, incubated for 15 minutes at 37°C in 
trypsin EDTA, dispersed in growth media (DMEM supplemented with 10% fetal calf 
serum (FCS), 2 mM glutamine, 10 kU/ml penicillin, 10 mg/ml streptomycin and 200 µM β-
mercaptoethanol) and plated on a 10 cm dish. Cells were split 2-3 days later into two 
15 cm dishes and after a further 2-3 days they were frozen at passage 2. Cells were 
cultured in conventional cell culture incubators at atmospheric oxygen or at 5% oxygen. 
For low oxygen concentrations (1% oxygen) cells were cultured in an oxygen glove-box 
incubator (INVIVO2 400, Ruskinn). 
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2.3.2  Isolation and culturing of epithelial kidney cells 
Kidneys were dissected from two month-old floxed mice. After removing the capsule 
under sterile conditions, kidneys were mashed with a razor blade on ice and digested in 
collagenase II solution at 37°C for 30 minutes. The cell suspension was filtered through a 
70 µm cell strainer and washed in HBSS + 5% FCS. Erythrocytes were lysed for 
1 minute using standard ACK buffer. Cells were re-suspended in complete K-1 culture 
medium (Dulbecco's modified Eagle's medium (DMEM):Hams F12) (50:50), 
supplemented with 0.5% fetal calf serum, 2 mM glutamine, 10 kU/ml penicillin, 10 mg/ml 
streptomycin, hormone mix (5 µg/ml insulin, 1.25 ng/ml prostaglandin E1 (PGE1), 
34 pg/ml triiodothyronine, 5 µg/ml transferrin, 1.73 ng/ml sodium selenite, and 18 ng/ml of 
hydrocortisone) and 25 ng/ml epidermal growth factor (EGF). Cells were counted and 
seeded at a density of 1x106 cells on standard 10 cm plastic tissue culture plates. After 5-
6 days in culture, cells were infected with adenoviruses expressing GFP (Adeno-GFP) or 
Cre-GFP (Adeno-Cre).  
 
2.3.3 Proliferation assays 
For MEF proliferation assays, cells were seeded at densities of either 2x105 or 3x105 
cells per 6 cm dish in triplicate dishes and counted after three days before reseeding at 
the same density for the next passage. All proliferation assays shown in all Figures are 
representative of at least three independent experiments. 
 
For primary kidney cells, a Sulforhodamine B (SRB) colometric assay was performed 
(Vichai and Kirtikara 2006). Cells were cultured in K-1 medium containing 10% fetal calf 
serum for two days before seeding for the SRB assay. 2x103 cells per well were seeded 
and fixed with 5% (wt/vol) trichloroacetic acid at the indicated time points, followed by 
staining with 0.057% (wt/vol) SRB solution and air drying. SRB was solubilized by 
incubation in 10 mM Tris base solution (pH 10.5) and OD was measured at 540 nm in a 
microplate reader (Anthos Lucy 3). 
 
2.3.4 Transformation assays  
For colony forming assays, testing the immortalization capacity, 5000 cells were seeded 
per 10 cm plate. After ten days, cells were washed with PBS and stained with crystal 
violet (0.3% crystal violet in 70% methanol) at room temperature. After 1 hour, cells were 
washed with tap water and air dried.  
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For soft agar assays, 2% low melting temperature agarose was dissolved in ddH2O and 
mixed 1:1 with 2x DMEM mix (20% FCS, 4 mM glutamine, 20 kU/ml penicillin, 20 mg/ml 
streptomycin, pH 7.4). 1 ml solution was distributed per well of a 12-well plate and 
allowed to set at room temperature. For the middle layer, 0.8% low melting agarose was 
dissolved in ddH2O and mixed 1:1 with 2x DMEM mix containing 1x105 cells per 
genotype. Subsequently, 1 ml cell suspension was distributed in triplicates (final cell 
number: 2.5x104 per well), and allowed to set for 30 minutes at room temperature. 
Finally, the layers were covered with 0.5 ml normal medium to prevent dehydration.  
 
For primary kidney cells, 2x K-1 medium (31.2 g/l DMEM/F12, 2.4 g/l sodium 
bicarbonate, 20% FCS, 20 kU/ml penicillin, 20 mg/ml streptomycin, 5 µg/ml insulin, 
1.25 ng/ml prostaglandin E1 (PGE1), 34 pg/ml triiodothyronine, 5 µg/ml transferrin, 
1.73 ng/ml sodium selenite, and 18 ng/ml of hydrocortisone, pH 7.4) was used instead of 
2x DMEM mix.  
 
For anchorage independent growth assays, 1x105 cells were seeded in untreated 
polystyrene plates to reduce cell attachment. Medium was changed by filtering the cells 
in cell strainers (pore size 40 – 100 µm). 
 
2.3.5 Starvation assays 
For starvation experiments 2.5x105 (for 24 hour starvation) or 3x105 (for 2 and 6 hours 
starvation) cells were seeded the day before. Cells were washed twice with PBS and 
appropriate media was added. After 2, 6 or 24 hours cells were trypsinised and the 
cellular ATP levels were determined as characterized below (2.4.1) and cells were 
harvested for Western blotting (see section 2.6). The used media was DMEM 
supplemented with 10 kU/ml penicillin and 10 mg/ml streptomycin and the ingredients 
shown in the table below. 
 
 glucose glutamine FCS 
low glucose 1 g/l  2 mM 10% 
no glucose - 2 mM 10% 
no glutamine 4.5 g/l  - 10% 
low FCS 4.5 g/l  2 mM 1% 
 
 
To prepare medium with lower amino acid content, normal DMEM media without 
glutamine was diluted with the corresponding volume of amino-acid-free DMEM (0.2 g/l 
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CaCl2, 0.1 mg/l Fe(NO3)3, 0.2 g/l MgSO4, 0.4 g/l KCl, 3.7 g/l NaHCO3, 6.4 g/l NaCl, 
0.125 g/l NaH2PO4, 4.5 g/l glucose, 40% Vitamin solution, 10% dialysed FCS, 10 kU/ml 
penicillin and 10 mg/ml streptomycin).  
 
2.4 Cellular and biochemical assays 
2.4.1 ATP measurements 
Cells were trypsinised, counted (Beckman counter Vi-Cell XR and Z2) and 1.5x105 cells 
were resuspended in 75 µl PBS and 75 µl buffer (CellTiter-Glo Luminescent Cell Viability 
Assay, Promega). Cells were lysed for 10 minutes at room temperature and distributed 
as technical triplicates in an opaque 96-well plate. Luminescence signal was detected 
with a microplate reader (Anthos Lucy 3). Student’s t-test was performed for statistical 
analysis.  
 
2.4.2 Glutamine uptake 
To determine glutamine uptake in cells, 1x105 cells per 6-well plate were seeded in 
triplicates. The next day cells were incubated for 20 minutes with DMEM (10% FCS, 
2 mM glutamine, 10 kU/ml penicillin, 10 mg/ml streptomycin) supplemented with 1µM [U-
14C5]-glutamine. Cells were washed twice with ice-cold PBS, lysed for 1 hour with lysis 
buffer (0.2% SDS; 0.2 M NaOH) and radioactivity was measured by scintillation counting 
with the Tri-Carb B2910TR Liquid Scintillation Analyzer (PerkinElmer). 
 
2.4.3 Protein synthesis assay 
For the detection of protein synthesis cells were incubated for 1 hour in methionine 
depleted media (DMEM w/o methionine and cysteine supplemented with 10% dialysed 
FCS, 2 mM glutamine, 10 kU/ml penicillin and 10 mg/ml streptomycin) and for another 
hour in DMEM containing 20 µCi L-[35S]-methionine (70%)/ L-[35S]-cysteine (25%). As a 
negative control cells were incubated in the same media supplemented with 10 µg/ml 
cycloheximid. Cells were washed twice in ice-cold PBS and lysed in buffer containing 
10 mM Hepes/KOH (pH 8), 1.5 mM MgCl2, 10 mM KCl and 0.5% NP-40 supplemented 
with EDTA-free protease inhibitors for 15 minutes on ice. Lysates were centrifuged for 
15 minutes and the protein concentration was determined by Bradford protein assay. The 
total protein (15 µg) was precipitated by 10% trichloroacetic acid, washed twice in ice-
cold acetone and radioactivity was measured by scintillation counting with the Tri-Carb 
B2910TR Liquid Scintillation Analyzer (PerkinElmer). 
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2.4.4 Extracellular flux and mitochondrial oxygen consumption  
The Seahorse Bioscience XFe96 Extracellular Flux Analyzer (Seahorse Bioscience, 
North Billerica, MA, USA) was used for the measurement of mitochondrial oxygen 
consumption and extracellular acidification in MEFs. Therefore 5x104 cells were seeded 
per well in 12 wells of XFe 96-well cell culture microplates in 200 µl of DMEM and 
incubated overnight (14–16 hours) at 37°C in 21% CO2. The next day the growth medium 
was replaced with 175 µl of bicarbonate-free DMEM (25 mM glucose, 110 mg/l 
sodiumpyruvate, 2 mM glutamine, pH 7.4) pre-warmed at 37°C. Before starting the assay 
procedured cells were preincubated at 37°C for 1 hour for degassing. For the 
measurement of oxygen consumption rate (OCR) and extracellular acidification rate 
(ECAR) 5 cycles of mix/wait/measure times of 3/3/3 minutes were used. The protein 
abundance was determined via Bradford assay.  
 
2.4.5 Metabolomics 
For metabolomic analysis 1x105 cells were seeded in triplicates on a 6-well plate. When 
cells reached 80% confluency the plates were washed twice with prewarmed wash 
solution (75 mM (NH4)2CO3 pH 7.4, 37°C) and frozen by slowly immersing the plate in 
liquid nitrogen. The plates were stored at -80°C until further analysis. For cell extraction 
700 µl prewarmed extraction solution (70% EtOH, 75°C) was added to each well of the 
plates and were placed on a heating block at 75°C. The closed plates were shaked for 
3 minutes on the heating block. After removing the solution, another 700 µl prewarmed 
extraction solution was added to the plates and gently agitated for further 2 minutes. The 
extracts were pooled and stored at -80°C until further analysis. Quantification of 
metabolites was performed on an Agilent 6550 QTOF instrument by flow injection 
analysis time-of-flight mass spectrometry (Fuhrer et al., 2011). All samples were injected 
in duplicates. Ions were annotated based on their accurate mass and the Human 
Metabolome Database reference list allowing a tolerance of 0.001 Da (Wishart et al., 
2013). Unknown ions and those annotated as adducts were discarded.  
 
2.4.6 FACS analysis 
For the detection of mitochondrial content in MEFs FACS analysis were used. After 
trypsinising, cells were washed twice in pre-warmed PBS and incubated for 30 minutes 
at 37°C with 100 nM NAO (mitochondria) in PBS with 10% FCS. Samples were analysed 
by flow cytometry using FACSCanto II machines. Data were quantitated using WinMDI 
software. 
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2.5 Real time PCR-analysis 
Total RNA was prepared from cultured cells or from powdered tissue of whole kidneys 
using NucleoSpin RNA kit and cDNA synthesis was done with random 
hexadeoxynucleotide primers and Ready-To-Go You-Prime First-Strand Beads. The real-
time PCR analysis of cDNA was performed with SYBR Green JumpStart Taq ReadyMix 
and used primers listed above (2.1.5). 
 
2.6 Western blotting 
Protein extracts from cultured cells were prepared by washing the cells twice with cold 
PBS and lysing  in RIPA buffer (50 mM Tris–HCl at pH 7.5, 150 mM sodium chloride, 
1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 2mM EDTA, 1 mM sodium fluoride, 
1 mM Na3VO4, 1 mM PMSF, 1 mM dithiothreitol, 1:100 Protease Inhibitor Cocktail).  
 
For the preparation of nuclear extracts cells were washed once in PBS and subsequently 
incubated for 20 minutes on ice in lysis buffer (10 mM HEPES, KOH pH 7.9, 10 mM KCl, 
0.1 mM EDTA, 0.1 mM EGTA, 1:100 Protease Inhibitor Cocktail, and 1 mM PMSF) 
followed by addition of NP-40 to a final concentration of 0.1%, vortexing and spinning at 
5000 rpm. The nuclear pellet was extracted for 20 minutes on ice with frequent agitation 
in protein extraction buffer (400 mM NaCl, 20 mM HEPES, KOH pH 7.9, 1 mM EDTA, 
1mM EGTA, 1:100 Protease Inhibitor Cocktail, and 1 mM PMSF). To remove insoluble 
material the lysates were centrifuged at 14000 rpm and 4°C for 10 minutes.  
 
For mitochondrial extracts cells were lysed in TES buffer (25 mM Tris/HCl, 0.2 mM 
EDTA, 0.33 M sucrose, pH 8) supplemented with 1:100 Protease Inhibitor Cocktail. Cells 
were than homogenized with a 1 ml syringe with a 29 gauge needle for 8-10 strokes. The 
solution was centrifuge at 1000 rpm for 10 minutes at 4°C. The supernatant was 
centrifuged again at 12000 rpm for 10 minutes at 4°C. The pellet contained the crude 
mitochondrial fraction, the supernatant the cytosolic fraction. Afterwards, the pellet was 
washed twice with TES buffer, resuspended in RIPA buffer and kept at −80°C until 
further analysis. 
 
Using the Bradford protein assay cleared protein lysates were quantitated using bovine 
serum albumin as a standard. Prior to use, samples were boiled for 5 minutes at 95°C. 
Proteins were run on 6–15% acrylamide gels, transferred to nitrocellulose membranes 
and visualized by semi-dry immunoblotting with antibodies described above (2.1.4). The 
signal was detected using the Fujifilm Luminescent Image Analyzer LAS4000 mini. 
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2.7 Mouse maintenance 
2.7.1 Mouse strains  
Rb1fl/fl (Marino et al. 2000), Vhlfl/fl (Haase et al. 2001), Trp53fl/fl (Jonkers et al. 2001) mice 
were crossed with Ksp1.3-Cre-ERT2 (Patel et al. 2008) mice to generate Ksp1.3-Cre-
ERT2; Vhlfl/fl; Rb1fl/fl; Trp53fl/fl, Ksp1.3-Cre-ERT2; Vhlfl/fl; Rbfl/fl, Ksp1.3-Cre-ERT2; Rbfl/fl; 
Trp53fl/fl, Ksp1.3-Cre-ERT2 Tg/+; Rb1fl/fl. Previously described Ksp1.3-Cre/+; Vhlfl/fl (Frew et 
al. 2008) and Ksp1.3-Cre/+; Trp53fl/fl (Wild et al. 2012) mouse strains were interbred to 
generate Ksp1.3-Cre/+; Vhlfl/fl; Trp53fl/fl mice. Non-Cre transgenic littermate mice served 
as controls for all cohorts. SCID/Beige mice (C.B-17/IcrHsd-Prkdcscid Lystbg-J) were 
obtained from Harlan Laboratories (USA). Wild type cells were isolated from C57BL/6 
embryos (Janvier Labs (USA)).  
 
2.7.2 Genotyping 
Ear biopsies were digested for 15 minutes at 95°C in lysis buffer (25 mM NaOH, 0.2 mM 
EDTA, pH 12) and thereafter neutralised with the same amount of neutralisation buffer 
(40 mM Tris-HCl, pH 5). The PCR reaction was carried out according to standard 
procedures using JumpStart Taq DNA polymerase and the primers shown in table 2.1.5. 
The DNA was analyzed on 1.5% agarose gels in SBE buffer (5 mM NaOH buffered with 
boric acid, pH 8.5). 
 
2.7.3 Tamoxifen treatment 
Ksp1.3-Cre/ERT2 transgenic mice were administered tamoxifen for induction of Cre/loxP 
recombination. Tamoxifen was dissolved in 100% ethanol and diluted 10-fold in corn oil 
to a final concentration of 20 mg/ml. Mice were injected intra peritoneal with tamoxifen 
(4 mg/40 g body weight) at P35 for 5 consecutive days and at P11 only once. To induce 
recombination in newborn mice, nursing dams were injected with tamoxifen (4 mg/40 g 
body weight) on post-partum days 2-4. Non-Cre transgenic littermate mice served as 
controls for all cohorts. 
 
2.7.4 Xenograft assay  
3-5x106 cells were detached with Accutase and resuspended in 70 µl DMEM. Cells were 
placed in a pre-cooled 30 gauge syringe and mixed with 70 µl ice cold matrigel. Syringes 
were kept on ice to avoid hardening of matrigel. SCID/Beige mice were anaesthetized by 
inhalation of 2% isofluorane using oxygen as carrier gas, shaved at both flanks and cells 
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were slowly injected subcutaneously. Mice were euthanized the latest when xenograft 
size reached a size of 1 cm3. The xenograft was fixed in 10% formalin and processed as 
described below (2.8). 
 
2.8 Tissue collection and procedure  
Mouse tissues were immersion-fixed in 10% formalin at 4°C overnight and stored in 70% 
ethanol. After dehydration in serial dilutions (3 hours 70% EtOH, 2 hours 80% EtOH, 
2 hours 90% EtOH, 2 hours 96% EtOH, 2 hours 100% EtOH, 2 hours xylene, 3 hours 
paraffin at 65°C), organs were embedded in paraffin and cut into 5 µm sections and fixed 
on polysine glass slides (VWR).  
 
2.9 Histological analysis  
2.9.1 Haematoxylin and Eosin (H&E) staining   
Tissue sections were de-waxed for 3 minutes in xylene and hydrated for 2 minutes each 
in serial dilutions of ethanol washes (100%, 95%, 70%). Nuclei were stained for 
4 minutes in haematoxylin and dipped three times in 0.3% acid alcohol for differentiation. 
Proteins were stained for 8 minutes in 1% eosin solution. Finally, specimen were 
dehydrated for 2 minutes in serial ethanol dilutions (70%, 95%, 100%), 3 minutes in 
xylene and mounted in entellan. 
 
2.9.2 Immunohistochemistry 
Tissue sections were de-waxed in xylene and hydrated in series of ethanol washes 
(10 minutes xylene, 100 % EtOH, 95% EtOH and 5 minutes in 70% EtOH) and washed 
for 5 minutes in PBS-T  (137 mM NaCl, 2.7 mM KCl, 19 mM Na2HPO4, 1.7 mM KH2PO4, 
pH 7.4, 0.3% Triton X-100). For antigen retrieval, slides were cooked for 5 minutes at 
110°C in 0.1 M citrate buffer (pH 6) using a standardized pressure cooker (HistosPro, 
Milestone). Next, specimens were incubated in peroxidase blocking solution (3% H2O2  in 
10% methanol) for 30 minutes, circled with a hydrophobic pen and incubated in protein 
blocking solution (PBS, supplemented with 10% goat serum, 0.3% Triton X-100, 1 drop 
avadin per 250 µl solution). Primary antibodies were diluted in PBS, containing 10% goat 
serum, 0.3% Triton X-100 and 1 drop biotin solution per 250 µl blocking buffer) and 
sections were incubated overnight at 4°C. Biotinylated secondary antibodies were diluted 
(10% goat serum in PBS) and applied for 1 hour at room temperature. Sections were 
washed and subsequently incubated in TBS (20 mM Tris, 150 mM NaCl, pH 7.6) for 
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10 minutes. For complex formation, 1 drop Avadin DH and 1 drop biotinylated 
horseradish peroxidase were mixed in 2.5 ml TBS 30 minutes prior to use, and solution 
was applied for 1 hour at room temperature. Next, specimen were washed in TBS and 
incubated in 50 mM Tris (pH 7.6). 3,3’-diaminobenzidine (DAB) was used as a 
chromogen according to the manufacturer’s instructions. Finally, the specimens were 
counterstained with hematoxylin solution for 30 seconds, dehydrated in serial ethanol 
dilutions (1 minute 70% EtOH, 2 minutes 95% EtOH and 100% EtOH, 3 minutes in 
Xylene) and mounted in entellan. All incubations were performed in a humidified 
chamber. Between incubations, sections were washed three times for 5 minutes in PBS, 
unless otherwise stated.  
 
Immunohistochemistry targeting Hifα and Rb1 proteins was performed using the Dako 
Catalyzed Signal Amplification (CSA) kit according to the manufacturer’s instruction. The 
following changes were included in the protocol: After peroxidase block, specimen were 
incubated for 15 minutes in Avadin solution (TBS, supplemented with 1% BSA, 0.1% 
Tween-20, 2 drops Avadin solution per 250 µl solution), followed by 15 minutes biotin 
solution (TBS, containing 1% BSA, 0.1% Tween-20 and 2 drops biotin solution per 250 µl 
solution). For washing, standard TBS-T (50 mM Tris, 150 mM NaCl, 0.1% Tween-20) 
was used before primary antibody incubation, whereas high salt TBS-T (0.05 M Tris-HCl 
pH 7.6 containing 0.3 M NaCl and 0.1% Tween-20) was used afterwards. Rehydration of 
sections, antigen retrieval and counterstaining was performed as described above. 
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3 Combined mutation of Vhl and Trp53 causes renal cysts and 
tumours in mice 
During the initial part of my PhD work I participated in a project that analysed the effects 
of deletion of Vhl and Trp53 in the epithelium of mouse kidneys and genital-urinary tract. 
This publication forms the first Results chapter and several conclusions are relevant for 
the rationale and understanding of the results presented in the subsequent Results 
chapters. In summary, these studies revealed that double deletion of Vhl and Trp53 
causes the formation of simple cysts, atypical cysts and neoplasms in the kidneys, and 
deletion in the epithelia of the genital urinary tract leads to dysplasia and tumour 
formation. Mouse embryonic fibroblasts undergo senescence when the Vhl gene is 
deleted. We discovered that this phenotype is rescued by the co-deletion of Trp53. The 
loss of Vhl and Trp53 results in the immortalisation but not in the transformation of these 
cells. The growth of Vhl deficient cells is largely independent of oxygen concentrations. 
Personally I answered the question that the culturing of these cells in 5% compared to 
21% oxygen leads to a partial but not full restoration of proliferative capacity (Figure 1G 
and 1H of (Albers et al. 2013)) and performed several experiments relating to analyses of 
MEFs deficient for Vhl and/or Trp53. Due to these findings all of the following 
experiments described in this thesis were performed at 5% oxygen in a cell culture 
incubator.  
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4 Metabolic profiling of Vhl negative cells 
4.1 Introduction and Aims 
The initial event in sporadic as well as hereditary ccRCC is the biallelic inactivation of the 
tumour suppressor protein pVHL. pVHL is involved in the regulation of diverse cellular 
processes whose dysregulation could be imagined to play a role in tumour formation 
(Frew and Krek 2007). Amongst other functions, the loss of VHL stabilises HIFα 
transcription factors which have multiple functions in proliferation, angiogenesis, 
apoptosis, invasion, metastasis and glucose metabolism (Gordan and Simon 2007). The 
HIF transcription factors are key regulators of glycolysis and oxidative phosphorylation, 
inducing the Warburg effect, characterised by increased glucose uptake and excretion as 
lactate at the expense of entry of pyruvate into the mitochondria for metabolism in the 
TCA cycle. This form of metabolism is a less efficient way of producing ATP but more 
importantly glucose breakdown via glycolysis provides the building blocks necessary for 
macromolecule biosynthesis that supports cellular proliferation (Vander Heiden et al. 
2009).  
 
Despite the diverse pathways that VHL and HIF regulate, mouse studies demonstrated 
that neither the loss of Vhl nor the activation of Hif1α or Hif2α could induce the formation 
of tumours in mouse kidneys. Most likely other mutations have to occur on top of the 
deletion of Vhl to promote cancer development (Frew et al. 2008; Fu et al. 2011; Fu et al. 
2013). Recent studies provided new insights in common mutations in ccRCC. 
Interestingly, besides VHL dysregulation, no other mutations occur with such a high 
frequency in sporadic ccRCC. However, some well-known tumour suppressors or 
oncogenes are mutated, but with a much lower frequency. These studies showed that it 
is more likely that whole pathways are dysregulated. In sporadic ccRCC the PI3K-AKT-
mTOR axis is mutated in up to 28% of cases, leading to increased mTORC1 signalling. 
As mTOR is the key regulator of cell growth and proliferation it is perhaps not surprising 
that mutations in this pathway occur frequently in ccRCC (Sato et al. 2013).  
 
In this chapter we sought to define the effects of loss of Vhl in mouse embryonic 
fibroblasts (MEFs) on the metabolism of glucose and glutamine as a model for the initial 
genetic event in ccRCC progression, namely the mutation of VHL in an otherwise 
genetically normal cell. We investigated how this is mediated by the stabilisation of the 
Hif1α and Hif2α transcription factors. Furthermore, we tried to determine the importance 
of dysregulated metabolic processes after loss of pVHL function on cell proliferation and 
their implication for tumour formation.  
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4.2 Results 
4.2.1 Warburg-like phenotype in Vhl and Vhl/Trp53 deficient cells 
We focused our first analyses on the metabolism of glucose via glycolysis and oxidative 
phosphorylation. To address this question, the expression levels of several known Hif1α 
target genes that are enzymes in these metabolic pathways were analysed in Vhlfl/fl as 
well as in the senescence rescued Vhlfl/fl Trp53fl/fl MEFs. This latter genotype was 
important as it allowed us to rule out that gene expression changes are a result of 
general effects of senescence rather than specific effects of loss of Vhl. Cells were 
infected with adenovirus expressing GFP as control (Adeno-GFP) or expressing Cre 
recombinase (Adeno-Cre) to induce deletion of the floxed genes. In both genotypes the 
genes Glut1, Pfkfb3, Pgk1, Ldha and Pdk1 showed a higher expression after the deletion 
of Vhl (Figure 4.1A, B). The gene products Glut1, Pfkfb3 and Pgk1 are involved in 
inducing glycolysis and Lda-A and Pdk1 prevent glucose from entering the TCA cycle. 
This effect is due to the loss of Vhl as control cells (Trp53fl/fl and wild-type) did not show 
any alterations (Figure 4.1C, D). Analyses of Vhlfl/fl Hif1afl/fl, Vhlfl/fl Hif2afl/fl and 
Vhlfl/fl Hif1afl/fl Hif2afl/fl MEFs revealed that the upregulation of these genes is dependent 
on Hif1α activity but not on Hif2α activity (Figure 4.1E-G). 
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Figure 4.1: Upregulation of glycolytic genes in Vhl negative MEFs is dependent on Hif1a but not on 
Hif2a. 
A-G Real-time quantitative PCR analysis of Hif1α target genes. mRNA abundance was normalized to S12 
mRNA abundance in Vhlfl/fl (A), Vhlfl/fl Trp53fl/fl (B), Trp53fl/fl (C), wild-type (D), Vhlfl/fl Hif1afl/fl (E), Vhlfl/fl 
Hif2afl/fl (F) and Vhlfl/fl Hif1afl/fl Hif2afl/fl (G) MEFs infected with adenoviruses expressing GFP (GFP) or 
Cre-GFP (Cre) (Student´s t-test, *p < 0.05, **p < 0.01, ***p < 0.001). 
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The upregulation of glycolytic genes in Vhl negative cells could be confirmed with 
elevated protein levels of Ldh-A and Pdk1 (Figure 4.2A). These findings suggested that 
Vhl deficient MEFs would exhibit an upregulation of glycolytic flux to lactate and a 
decrease of entry of pyruvate into the mitochondria for metabolism by oxidative 
phosphorylation. In both Vhl and Vhl/Trp53 mutant cells the acid efflux (ECAR) 
(Figure 4.2B) as well as the amount of lactate released into the media (Figure 4.2C) and 
glucose uptake (Figure 4.2D) were significantly increased. In parallel to the ECAR 
measurement, the oxygen consumption rate (OCR) was detected as a readout of 
mitochondrial respiration. OCR was highly decreased in Vhl negative cells (Figure 4.2E). 
This effect was not due to a reduction in the mitochondrial content (Figure 4.2G, H). If 
these results are considered together, a clear shift from oxidative phosphorylation 
towards aerobic glycolysis is visible. Since oxidative phosphorylation of glucose-derived 
carbons represents the major source of cellular ATP, we predicted that ATP levels may 
be affected in Vhl mutant cells. Indeed, the ATP levels in Vhlfl/fl as well as in Vhlfl/fl Trp53fl/fl 
MEFs were significantly decreased (Figure 4.2F). The fact that the ATP levels were not 
restored in Vhl/Trp53 deficient cells indicates that a mechanism other than senescence 
has to be responsible for this. Parallel studies in our laboratory showed that the 
decreased levels of ATP are entirely dependent on Hif1a and not on Hif2a (data not 
shown, Désirée Schönenberger), consistent with the effects of gene deletion on glycolytic 
gene expression in these cells (Figure 4.1E-F). Thus, Hif1α activation in MEFs causes a 
Warburg-like shift in glucose metabolism with a small increase in glucose uptake and 
metabolism to lactate but a large drop in oxidative phosphorylation that leads to a 
deficiency in ATP production.  
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Figure 4.2: Warburg-like metabolism in Vhl negative MEFs causes ATP deficiency. 
A Western blotting analysis of wild-type, Vhlfl/fl, Trp53fl/fl and Vhlfl/fl Trp53fl/fl MEFs infected with 
adenoviruses expressing GFP or Cre. 
B-F Measurements of glycolytic parameters in wild-type, Vhlfl/fl, Trp53fl/fl and Vhlfl/fl Trp53fl/fl MEFs: 
(B) extracellular acidification rate (ECAR), (C) relative lactate production, (D) glucose utilisation, 
(E) oxygen consumption rate (OCR) and (F) relative ATP levels (Student´s t-test, *p < 0.05, **p < 0.01, 
***p < 0.001). 
G, H FACS analysis of Vhlfl/fl (G) and Vhlfl/fl Trp53fl/fl (H) MEFs using NAO as a dye for quantification of 
mitochondria. 
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During glycolysis the cytosolic balance of NAD+/NADH ratio is shifted as the metabolism 
of glucose to pyruvate also generates NADH. In cells with a low rate of glycolysis the 
regeneration of NAD+ in the cytosol can occur through malate-aspartate shuttles but in 
highly proliferating cells with highly increased glycolysis this mechanism of NAD+ 
generation are likely saturated (Locasale and Cantley 2011). Therefore, other 
mechanisms like reduction of pyruvate to lactate are required to regenerate NAD+ from 
NADH. We were now wondering if increased glycolysis in Vhl deficient cells affects the 
levels of NAD+ and its reduced form NADH. Interestingly, NAD+ as well as NADH levels 
were increased in Vhl negative cells, but the ratio of NAD+/NADH did not differ compared 
to control cells (Figure 4.3A, C). The levels of NADH in Vhl/Trp53 and Trp53 negative 
MEFs were slightly increased, resulting in a decrease in the ratio of NAD+/NADH 
(Figure 4.3B-D). In skeletal muscle cells an activation of AMPK could increase the 
amount of NAD+ and also the ratio NAD+/NADH (Canto et al. 2009). The activation of 
AMPK in Vhl deficient cells will be discussed in the following paragraph (4.2.2).  
 
 
 
Figure 4.3: Increased levels of NAD+ and NADH in Vhl deficient MEFs. 
A-D Intracellular NAD+ and NADH levels of Vhlfl/fl, Vhlfl/fl Trp53fl/fl and Trp53fl/fl MEFs infected with 
adenoviruses expressing GFP or Cre. 
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In order to gain deeper insights into metabolic changes of Vhl deficient cells and to better 
understand integrated metabolic responses we performed mass spectrometry-based 
metabolomic analyses. With this technique it is possible to simultaneously monitor and 
quantify the abundance of hundreds of intracellular metabolites like cofactors, energy 
equivalents and primary metabolites (Fuhrer et al. 2011). For these experiments, we 
used wild-type, Vhlfl/fl, Trp53fl/fl and Vhlfl/fl Trp53fl/fl primary MEFs treated with adenovirus 
expressing GFP or GFP-Cre. For the analysis knockout cells were compared to control 
cells (Adeno-GFP treated). These experiments yielded rather inconsistent results 
between replicates and independent experiments, complicating analyses. The only 
partially consistent changes observed were that Vhl and Vhl/Trp53 deficient cells 
compared to their control cells showed an increase of intermediates of the pentose 
phosphate pathway. However, in different experiments not always the same 
intermediates could be detected and also the detected amount varied (Figure 4.4). 
Another problem was the detection of baseline differences in wild-type GFP treated 
compared to wild-type Cre treated cells and also in various experiments the profiles 
differed quite a lot. Furthermore, the intensity of the detected peaks was much lower than 
expected. Despite several trials these problems could not be solved satisfyingly and this 
experimental approach was not further pursued.  
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Figure 4.4: Deficiency of Vhl increases pentose phosphate pathway intermediates.  
Tree-chart of metabolomic profiling of wild-type, Trp53fl/fl, Vhlfl/fl and Vhlfl/fl Trp53fl/fl MEFs infected with 
adenoviruses expressing GFP or Cre. 
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4.2.2 Activation of AMPK in Vhl negative MEFs 
The energy status in cells is sensed by the AMP-activated protein kinase (AMPK) due to 
changes in the ratio of AMP to ATP that are caused by metabolic stresses like hypoxia, 
ischemia and oxidative and hyperosmotic stresses. Activated AMPK is responsible for 
the activation of catabolic processes like glycolysis and fatty acid synthesis and the 
inhibition of anabolic events including lipid, protein and glycogen synthesis (Hardie 
2004). As the levels of ATP were decreased in Vhl knockout cells, the activation status of 
AMPK was examined via detection of the phosphorylation status of Thr172. Despite 
observing consistently decreased ATP levels in Vhl negative cells (Figure 4.2F), AMPK 
was clearly activated in some experiments (Figure 4.5A, B) but not in others 
(Figure 4.5C) although the knockout efficiency for Vhl was very consistent. One possible 
explanation for this inconsistency could be that unknown factors, which are not directly 
associated with the loss of Vhl, also impact the phosphorylation status of AMPK.  
 
 
 
Figure 4.5: Activation of AMPK in Vhl deleted MEFs is inconsistent. 
A-C Western blotting analysis of multiple independent experiments using wild-type, Vhlfl/fl, Trp53fl/fl and Vhlfl/fl 
Trp53fl/fl MEFs infected with adenoviruses expressing GFP or Cre. 
 
To attempt to understand these inconsistent phosphorylation events, different starvation 
experiments were performed in Vhl negative cells. We hypothesised that the induction of 
additional stress might help to answer the question of which factors have a further effect 
on the ATP levels and the activation of AMPK. We further hypothesised that Vhl deficient 
cells might be hypersensitive to metabolic changes induced by starvation, for example, 
they may be highly dependent on glucose or glutamine for energy production. Therefore, 
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Vhlfl/fl and Vhlfl/fl Trp53fl/fl MEFs were starved for two or six hours of glucose or glutamine. 
Surprisingly, the ATP levels in all Vhl deficient cells were rescued due to the withdrawal 
of glucose at both time points, contrary to our initial expectations. This may possibly be 
due to activation of other metabolic pathways that allow ATP generation from glycogen 
stores or fatty acids, or potentially from the induction of autophagy. Glutamine deprivation 
for six hours moderately decreased ATP levels in wild type cells and also caused a 
similar moderate decrease in Vhl deficient cells (Figure 4.6A, C). Glucose deprivation in 
general increased the amount of phosphorylated AMPK but the deletion of Vhl had no 
additional effect (Figure 4.6B, D).  
 
 
 
Figure 4.6: Vhl deficient cells are not sensitised to glucose or glutamine starvation. 
A, C Cellular ATP levels of Vhlfl/fl and Vhlfl/fl Trp53fl/fl MEFs infected with adenoviruses expressing GFP or Cre 
starved of glucose or glutamine for 2 or 6 hours. 
B, D Western blotting analysis of cells from (A) and (C). 
 
Prolonged (24 hour) glucose or glutamine starvation of Adeno-GFP and Adeno-Cre 
treated Vhlfl/fl, Vhlfl/fl Trp53fl/fl and control cells (Trp53fl/fl and wild-type) showed decreased 
ATP levels in all genotypes but Vhl negative cells were not more sensitive to glutamine 
starvation (Figure 4.7A-D). In addition, Vhl/Trp53 knockout cells that were exposed for 
24 hours to media with reduced glucose, FCS or amino acids were analysed. However, 
neither the ATP levels (Figure 4.7E) nor the phosphorylation status of AMPK 
(Figure 4.7F) was further affected in any of these conditions. Energy stress-activated 
AMPK inhibits the mTORC1 pathway (Inoki et al. 2003; Gwinn et al. 2008) thus mTORC1 
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targets including ribosomal protein S6 or 4E-BP1 might be expected to show lower 
phosphorylation levels in Vhl deficient cells. However, after short term starvation (two 
and six hours) no changes in the phosphorylation states of these proteins could be 
observed (Figure 4.6B, D). Furthermore, in Adeno-GFP and Cre treated cells a starvation 
for 24 hours reduced phosphorylation levels of S6 protein only due to glucose withdrawal 
but this did not correlate with the phosphorylation levels of AMPK (Figure 4.7F). Taking 
the obtained results together, none of the performed experiments could explain the 
inconsistent phosphorylation pattern of AMPK. 
 
 
 
Figure 4.7: Long-term glucose or glutamine starvation reduces cellular ATP levels.  
A-D Cellular ATP levels of Vhlfl/fl (A), Vhlfl/fl Trp53fl/fl (B), Trp53fl/fl (C) and wild-type (D) MEFs infected with 
adenoviruses expressing GFP or Cre. Cells were starved for 24 hours of glucose or glutamine.  
E Cellular ATP levels of Vhlfl/fl Trp53fl/fl MEFs infected with GFP or Cre. Cells were treated for 24 hours 
with normal DMEM, DMEM with: 1g/l glucose, no glucose, no glutamine, 1% FCS or 20% amino acids. 
F Western blotting analysis of cells from (E). 
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4.2.3 Loss of Vhl does not activate p53  
One downstream target of AMPK is the tumour suppressor p53 that is also activated due 
to cellular damage or stress and induces cell cycle responses like apoptosis or growth 
arrest. AMPK phosphorylates and activates p53, which in turn induces cell cycle arrest in 
the G1/S phase of the cell cycle and this is accompanied by an upregulation of the p53 
target gene p21 (Jones et al. 2005). Since we initially observed that Vhl deletion induces 
senescence that is genetically dependent on Trp53, we hypothesised that energy 
deficiency may activate AMPK to induce p53 activity and thereby induce senescence. In 
Vhl deficient primary MEFs with activated AMPK, slightly increased protein levels of p53 
as well as of phosphorylated p53 could be observed. However, there was no change in 
the protein level of p21Cip (Figure 4.8A). Wild-type MEFs that were infected with an 
adenovirus expressing Cre also showed increased phosphorylation levels of p53 
(Figure 4.8A, B) and this was not further induced by knockdown of Vhl (Figure 4.8B). 
These findings argue that the observed induction of p53 phosphorylation may result from 
DNA damage induced by Cre activity (Loonstra et al. 2001). The results from protein 
analyses could be confirmed with data from quantitative RNA analyses where the p53 
target genes Mdm2, p21 and Tigar were not induced in cells with deleted Vhl (Figure 
4.8C-E). Altogether, these results demonstrated that the deletion of Vhl in MEFs and the 
resulting activation of AMPK did not induce a p53 response. The induction of p53 was 
rather likely to be a consequence of Cre expression, which has previously been shown to 
cut genomic DNA non-specifically and cause DNA damage (Loonstra et al. 2001). 
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Figure 4.8: Absence of p53 induction in Vhl knockout cells. 
A Western blotting analysis of wild-type, Vhlfl/fl, Trp53fl/fl and Vhlfl/fl Trp53fl/fl MEFs infected with 
adenoviruses expressing GFP or Cre. 
B Western blotting analysis of wild-type MEFs infected with GFP or Cre and/or lentiviruses expressing an 
empty pLKO.1 shRNA (shRNA-ns) or pLKO.1 shRNA directed against Vhl (shRNA-Vhl).  
C-E Real-time quantitative PCR analysis of Mdm2 (C), p21 (D) and Tigar (E) mRNA abundance normalized 
to S12 mRNA abundance in GFP or Cre infected wild-type, Vhlfl/fl, Vhlfl/fl Trp53fl/fl and Trp53fl/fl MEFs 
(Student´s t-test, *p < 0.05). 
 
4.2.4 Deletion of Vhl alone is not enough for consistent downregulation of 
the mTORC1 pathway 
Another target of AMPK is the mTORC1 complex that regulates cell growth by integrating 
nutrient and growth factor-derived signals to control protein synthesis. AMPK indirectly 
inhibits mTORC1 via phosphorylation of TSC2 (Inoki et al. 2003), a GTPase upstream of 
mTORC1 or directly by phosphorylation of RAPTOR (Gwinn et al. 2008), which is part of 
the mTORC1 complex (see also Figure 1.3). As a readout for the activity of the mTORC1 
complex its downstream targets ribosomal protein S6 kinase (S6K) and ribosomal protein 
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S6, which are phosphorylated when mTORC1 is active (Ruvinsky et al. 2005), were 
analysed. In Vhl negative cells a slight reduction of phosphorylated S6K and S6 protein 
could be observed when AMPK was activated, indicating an inhibition of mTORC1 
signalling. Since decreased levels of total protein levels of S6K and S6 were observed, 
we wondered if protein synthesis could be affected due to the loss of Vhl 
(Figure 4.9A, B). To address this question, a 35S-methionine incorporation assay was 
performed, which could detect a mild decrease of protein synthesis in Vhl knockout cells 
(Figure 4.9C, D). However, since these cells exhibit a slower rate of proliferation, it is 
possible that the reduced level of protein synthesis may be a consequence, rather than a 
cause, of the proliferation rate. As mentioned before, activated AMPK could not be 
observed in all analysed samples. The same was true for the decreased phosphorylation 
status of S6K and S6 protein that could also not be observed in all analysed samples 
from independent experiments (Figure 4.6B, D; Figure 4.7F). Again, we hypothesise that 
one or several unknown factors are influencing AMPK activity, which made further 
studies of potential downstream phenotypes very difficult.  
 
 
 
Figure 4.9: Downregulation of activated S6 and protein synthesis in cells with loss of Vhl. 
A, B Western blotting analysis of wild-type and Vhlfl/fl MEFs infected with adenoviruses expressing GFP or 
Cre. 
C, D Measurement of protein synthesis of wild-type and Vhlfl/fl MEFs infected with GFP or Cre by 
incorporation of 35S-methionine (Student´s t-test, *p < 0.05, **p < 0.01). 
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4.2.5 Induction of mTORC1 via loss of Tsc2 is insufficient for 
transformation 
An important conclusion of our analyses of the proliferation of Vhl/Trp53 mutant MEFs 
was that these cells are immortalised but proliferate more slowly than Trp53 null MEFs. 
We have also recently shown that the inhibitory effects on proliferation through loss of 
Vhl are mediated by Hif1α activation (Désirée Schönenberger, data not shown). We 
therefore wondered whether Hif1α-mediated metabolic changes could cause energy 
stress, AMPK activation and downregulation of the mTORC1 pathway, leading to 
lowered rates of proliferation. 
 
A natural self-protection of cells against excessive proliferation signals is the inhibition of 
the mTORC1 pathway via multiple feedback mechanisms. Additional mutations in 
pathways involved in cell proliferation might help to overcome the inhibition of the 
mTORC1 pathway, thus allowing uncontrolled cell growth. In ccRCC, multiple 
components of the PI3K-AKT-mTOR pathway are altered (TCGA 2013). The tumour 
suppressor genes TSC1 and TSC2, encoding hamartin and tuberin, form a complex that 
antagonises the mTORC1 pathway (Tee et al. 2002). AMPK operates on different levels 
as a counterpart of mTORC1. For example it phosphorylates and thus activates tuberin 
(also see Figure 1.3) (Inoki et al. 2003). To further address the question if suppression of 
the mTOR pathway is a barrier for prolonged proliferation, a knockdown of Tsc1 or Tsc2 
in Vhl/Trp53 deficient cells was introduced. Studies in our laboratory showed that 
knockdown of Tsc1 or Tsc2 causes Trp53-dependent senescence (Ana Filipa 
Gonçalves, data not shown) and Tsc1 or Tsc2 knockdown in Vhl deficient MEFs 
completely prevented cellular proliferation. In contrast, Tsc1 or Tsc2 were able to be 
knocked down in Vhl/Trp53 double mutant fibroblasts but this did not increase the 
proliferative rate of these cells (Figure 4.10A, B), despite activation of the mTORC1 
pathway, indicated by increased levels of phosphorylated ribosomal protein S6 and 
4E-BP1 (Figure 4.10C). A way to measure cellular immortalisation is the so-called colony 
formation assay in which immortalised cells, but not primary MEFs display the ability to 
proliferate to form colonies when plated at low density. In wild-type cells low cell density 
seeding causes a premature senescence program. We showed that Vhl/Trp53 null MEFs 
are immortalised (Albers et al. 2013). Vhl/Trp53 null cells with a knockdown of Tsc1 or 
Tsc2 were still able to form colonies in this assay (Figure 4.10D). Neither the additional 
loss of Tsc1 nor of Tsc2 caused a transformation of the Vhl/Trp53 negative cells as the 
cells were unable to grow in a soft agar assay (data not shown). While Tsc1 or Tsc2 
knockdown increased ATP levels in wild-type cells, there was no rescue of the low levels 
of ATP in Vhl/Trp53 null cells (Figure 4.10E). In summary, although the loss of Tsc1 or 
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Tsc2 induces activation of the mTORC1 pathway, the additional loss of Vhl and Trp53 is 
not sufficient for a transformation of primary MEFs. 
 
 
 
Figure 4.10: Deletion of Tsc1 or Tsc2 has no further proliferative effect on Vhl/Trp53 deficient cells. 
A, B Proliferation assay of Vhlfl/fl Trp53fl/fl MEFs infected with adenoviruses expressing GFP or Cre and 
lentiviruses expressing an empty pLKO.1 shRNA (shRNA-ns) or pLKO.1 shRNA directed against Tsc1 
or Tsc2 (shRNA-Tsc1 or Tsc2). 
C Western blotting analysis of cells from (A) and (B) at indicated time points. 
D Immortalisation assay of cells from (A) and (B). 
E Cellular ATP levels of cells from (A) and (B) 6 days after adenovirus infection. 
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4.2.6 Loss of Lkb1 does not cooperate genetically with loss of Vhl to cause 
transformation 
Since AMPK affects multiple cellular processes, other pathways in addition to regulation 
of mTORC1 signalling might be more relevant for the potential AMPK-mediated 
proliferation suppression following Vhl deletion. We therefore tested the idea that AMPK 
activation in general may represent a proliferation barrier in Vhl deficient cells. 
Alternatively, it could also be envisaged that loss of Vhl causes a metabolic stress and 
that AMPK activity is necessary to coordinate the cellular metabolic responses to this 
stress. The absence of correct AMPK activation could therefore be imagined to be 
protective and be necessary for the survival or proliferation of Vhl deficient cells. To 
better understand the effects of AMPK activation in Vhl deficient cells we knocked down 
the kinase that phosphorylates and activates AMPK in metabolic stress situations. The 
serine/threonine kinase LKB1 was originally identified as a tumour suppressor that is 
mutated in the Peutz-Jeghers hereditary cancer syndrome (Hemminki et al. 1998; Jenne 
et al. 1998). Recent studies have suggested that LKB1 might also act as a tumour 
suppressor in some sporadic cases of ccRCC (Duivenvoorden et al. 2013). Knockdown 
experiments of Stk11, the gene encoding Lkb1, were performed in Vhlfl/fl Trp53fl/fl primary 
MEFs treated with Adeno-Cre using four different shRNA hairpins. Unexpectedly, the 
hairpins behaved differently. Two of the Stk11 knockdowns (hairpin A and C) in 
Vhl/Trp53 deficient cells created a proliferative advantage whereas the other two hairpins 
(B and D) inhibited proliferation (Figure 4.11A, E). The reason for these phenotypic 
differences is not related to different knockdown efficiencies as protein and RNA 
abundance of Lkb1 was reduced similarly by all four hairpins (Figure 4.11C, D, F). 
Anchorage independent proliferation was measured by seeding cells in uncoated plates 
to reduce cell attachment. Interestingly, anchorage independent growth was only 
possible with hairpin C in Vhl/Trp53 deficient cells (Figure 4.11G) and these cells were 
able to form tumours in a xenograft assay (data not shown). However, since we could 
observe this effect only in cells infected with one of four hairpins and the different 
hairpins behaved differently in the proliferation assays it is impossible to draw 
conclusions from this experimental approach and the cooperative effects in 
transformation likely reflect an off-target effect of hairpin C. 
 
Figure 4.11: Lkb1 knockdown has inconsistent effects on Vhl/Trp53 knockout MEFs. 
A, E Proliferation assay of Vhlfl/fl Trp53fl/fl MEFs infected with adenoviruses expressing GFP or Cre and 
lentiviruses expressing an empty pLKO.1 shRNA (shRNA-ns) or four different pLKO.1 shRNAs directed 
against Stk11 (shRNA-Stk11 A-D). 
B, F Western blotting analysis of cells from (A and E) at indicated time points. 
C, D Real-time quantitative PCR analysis of Stk11 (C) and Vhl (D) mRNA abundance normalized to S12 
mRNA abundance in cells from (A). 
G Anchorage independent growth of cells from (A). Scale bar 50 µm. 
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Figure 4.11: Lkb1 knockdown has inconsistent effects on Vhl/Trp53 knockout MEFs. 
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4.2.7 Combined loss of pVhl and AMPK is insufficient to transform cells 
The AMPK enzyme is composed of three subunits. AMPKα1 and AMPKα2 are the 
catalytically active subunits in different complexes, encoded by Prkaa1 and Prkaa2, 
respectively (Stapleton et al. 1996). As an alternative approach to inhibiting AMPK 
activation by silencing Lkb1, we also directly examined the effects of genetic loss of 
AMPK on cellular behaviour of Vhl knockdown cells. SV40-T Antigen immortalised 
Prkaa1-null, Prkaa2-null or Prkaa1/2-null MEFs were used and a shRNA against Vhl was 
introduced. The proliferation pattern of these cells did not significantly differ with or 
without Vhl, only the Prkaa2-null cells showed a slight reduction in proliferative capacity 
(Figure 4.12A). A limiting factor in these experiments is that over time, as the cells are 
repeatedly passaged, all of the Vhl knockdown cultures became enriched with pVHL-
expressing cells (Figure 4.12B). This phenomenon of selection against efficient Vhl 
knockdown is described in Chapter 3. Interestingly, even though the knockdown of Vhl 
was initially very efficient, there were no effects on ATP levels (Figure 4.12C). One 
potential explanation for this might be related to findings in Chapter 6 in which we could 
show that loss of Rb1 function is sufficient to rescue the ATP deficiency in Vhl deficient 
cells. Since SV40-T Antigen inhibits both p53 and Rb protein functions, it could be that 
the transformed background of the AMPK-deficient MEFs provides a rescue of the ATP 
phenotype, making these cells an inappropriate model to study genetic interactions 
between loss of Vhl and loss of Prkaa1/2. 
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Figure 4.12: Knockdown of Vhl in AMPK negative cells is not enough for reduction of ATP levels. 
A Proliferation assay of SV40-TAg WT, Prkaa1 -/-, Prkaa2 -/-, Prkaa1/2 -/- MEFs infected with lentiviruses 
expressing an empty pLKO.1 shRNA (shRNA-ns) or pLKO.1 shRNA directed against Vhl (shRNA-Vhl). 
B Western blotting analysis of cells from (A) at indicated time points. 
C Cellular ATP levels of cells from (A) 6 days after lentiviral infection. 
 
To attempt to better address how the loss of AMPK affects Vhl-deficient cells, primary 
MEFs instead of SV40-T Antigen immortalised MEFs were used. Vhl/Trp53 negative 
MEFs were infected with shRNAs to induce the knockdown of Prkaa1, which was 
reduced to about 25-50% of normal levels (Figure 4.13D). The knockdown of Prkaa1 
decreased the proliferation rate of control cells (Adeno-GFP treated) dramatically 
(Figure 4.13A) showing that AMPKα1 activity is necessary for the proliferation of wild-
type cells. In Vhl/Trp53 negative MEFs the knockdown of Prkaa1 resulted in a growth 
disadvantage at the beginning of the proliferation curve, but the cells could at least 
partially recover over time (Figure 4.13A). The reduced ATP levels following Vhl/Trp53 
knockout were not further affected by the knockdown of Prkaa1 (Figure 4.13E). The 
isoform of AMPKα that is most highly abundantly expressed in MEFs is AMPKα1 
(Phoenix et al. 2012), (Figure 4.14A and Figure 4.13F). The knockdown of Prkaa1 was 
not compensated by elevated levels of Prkaa2 expression in control or in Vhl/Trp53 
negative MEFs (Figure 4.14B and Figure 4.13F). In summary these results point out that 
the loss of Prkaa1 in combination with Vhl/Trp53 deletion is not sufficient to enhance 
cellular proliferation, nor does it significantly compromise the ability of these cells to 
survive the metabolic alterations that are caused by loss of Vhl. 
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Figure 4.13: No pro-proliferative effect of Prkaa1 loss on Vhl/Trp53 deficient cells.  
A Proliferation assay of Vhlfl/fl Trp53fl/fl MEFs infected with adenoviruses expressing GFP or Cre and 
lentiviruses expressing an empty pLKO.1 shRNA (shRNA-ns) or two different pLKO.1 shRNAs directed 
against Prkaa1 (shRNA-Prkaa1 A or B). 
B-D Real-time quantitative PCR analysis of Vhl (B), Trp53 (C) and Prkaa1 (D) mRNA abundance normalized 
to S12 mRNA abundance in cells from (A). 
E Cellular ATP levels of cells from (A) 6 days after adenovirus infection. 
F Western blotting analysis of cells from (A) at indicated time points. 
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Figure 4.14: Knockdown of Prkaa1 does not increase Prkaa2 mRNA levels. 
A Real-time quantitative PCR analysis of wild-type MEFs infected with adenoviruses expressing GFP or 
Cre. The measured mRNA abundance of Prkaa1 and Prkaa2 was normalized to S12 mRNA 
abundance. 
B, C Real-time quantitative PCR analysis of Vhlfl/fl Trp53fl/fl (B) and Trp53fl/fl (C) MEFs infected with GFP or 
Cre and lentiviruses expressing an empty pLKO.1 shRNA (shRNA-ns) or different pLKO.1 shRNAs 
directed against Prkaa1 (shRNA-Prkaa1 A-D). The mRNA abundance of Prkaa1 and Prkaa2 was 
normalized to S12 mRNA abundance. 
 
4.3 Discussion 
Mouse embryonic fibroblasts as well as primary kidney cells undergo senescence when 
Vhl is deleted. Work described in this thesis contributed to the discovery that this effect 
occurs in a p53-dependent manner as in Vhl/Trp53 negative cells the senescence 
phenotype is rescued and cells proliferate in an immortalised manner. Interestingly, cells 
deficient for Vhl proliferate slower than Vhl positive cells even when cell cycle regulators 
like p53 and pRb are mutated. These observations indicate that additional cellular 
responses to loss of Vhl may represent barriers to transformation of primary cells and 
perhaps might represent barriers to tumour formation in vivo (Albers et al. 2013). So far it 
is still unknown if and how metabolic alterations following loss of pVHL contribute to 
tumour formation and whether these alterations may represent transformational barriers 
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or alternatively whether they may enable cellular transformation. One aim of this thesis 
was to define the effects of loss of Vhl in MEFs on the metabolism of glucose and 
glutamine as a model for the initial genetic event in ccRCC progression, namely the 
mutation of VHL in an otherwise genetically normal cell. We investigated how this is 
mediated by the stabilisation of the Hif1α and Hif2α transcription factors.  
 
In this thesis it could be shown that Vhl negative, as well as Vhl/Trp53 deficient MEFs 
exhibited a Hif1α-dependent Warburg-like metabolic phenotype with elevated expression 
of glycolytic genes, a small increase in glucose uptake and metabolism to lactate but a 
large decrease in oxidative phosphorylation (Figure 4.1 and 4.2). Since the rate of 
glycolytic flux was not increased to an extent that would compensate for decreased ATP 
production by mitochondrial oxidation, these cells exhibited lowered levels of ATP. Vhl 
and Vhl/Trp53 deficient MEFs both showed low ATP levels, indicating that this decrease 
is not simply a consequence of the senescence phenotype as Vhl/Trp53 knockout cells 
escape senescence. The impaired ATP generation might be one contributing factor to 
the initiation of senescence in primary Vhl deficient MEFs and impaired proliferation in 
Vhl/Trp53 negative MEFs since knockdown of Hif1a rescued ATP levels and rescued 
senescence and proliferation (Désirée Schönenberger, unpublished data). Several 
studies in different VHL-deficient ccRCC cancer cell lines revealed HIF1α and/or HIF2α-
dependent regulation of glucose transport, aerobic glycolysis and mitochondrial 
respiration and showed that restoration of VHL increased cellular ATP levels, arguing 
that the MEF model accurately reflects at least some of the metabolic features of ccRCC 
cells (see also section 1.2.1) (Papandreou et al. 2006; Langbein et al. 2008; Chan et al. 
2011). However, compared to the MEFs that we used which harbour exactly defined 
mutations, these ccRCC cell lines have a complex genetic background with additional 
mutations that emerged during tumour development. These mutations potentially brought 
further advantages that allowed these cells to deal with metabolic limitations imposed by 
constitutive HIFα activity and enabled them to form tumours. For example, in sporadic 
ccRCC, mutations could be detected leading to overexpressed C-MYC or activation of 
the PI3K-AKT-mTOR pathway, both of which control several cellular metabolic pathways 
(Sato et al. 2013). Thus, we speculate that additional mutations in Vhl/Trp53 negative 
cells that affect cellular metabolism could lead to their transformation. Indeed, 
unpublished studies in our laboratory show that c-Myc overexpression in Vhl/Trp53 
deficient MEFs and primary kidney cells causes their transformation (Tomas Hejhal, 
unpublished observations). In this context, a very recent publication showed that FBP1 
(fructose-1,6-bisphosphatase 1) is inhibited in almost 100% of analysed ccRCC tumour 
samples at the level of protein accumulation. FBP1 is the main enzyme of 
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gluconeogenesis, converting fructose-1,6-bisphosphate to fructose-6-phosphate, thus 
counteracting PFK1 (phosphofructokinase 1) (see also Figure 1.2). In addition, FBP1 
was shown to antagonize glycolytic flux and can directly inhibit HIF by interacting with the 
HIF inhibitory domain and thereby inhibiting glucose metabolism (Li et al. 2014). We 
speculate that FBP1 may counteract HIF activity in Vhl and Vhl/Trp53 deficient MEFs 
and therefore limit glycolytic flux, causing ATP deficiency. Selection for low levels of 
FBP1 may therefore overcome the potential barrier to tumour formation imposed by 
Hif1α. It would be very interesting to analyse glycolytic flux, oxidative phosphorylation, 
ATP production, proliferation and transformation in Vhl/Trp53 null MEFs with knockdown 
of Fbp1. 
 
Another interesting finding in Vhl and Vhl/Trp53 MEFs was increased levels of activated 
AMPK (Figure 4.5). This kinase is the energy sensor of cells that is activated by stress 
situations and maintains the energy balance in cells in response to changes in the ratio 
of AMP/ATP (Hardie 2011). One function of AMPK is to antagonize the mTORC1 
complex, a key regulator of cell growth and proliferation (Inoki et al. 2003; Gwinn et al. 
2008). In cancer cell lines, AMPK may function as a negative regulator of aerobic 
glycolysis and cellular biosynthesis as the downregulation of its activity promoted the 
Warburg effect and AMPK activation suppressed HIF1α translation by inhibiting 
mTORC1 (Faubert et al. 2013). An attractive hypothesis that we investigated was that 
AMPK exhibits tumour suppressor functions in MEFs with a deletion of Vhl/Trp53 which 
contributes to this mild Warburg effect and the proliferative deficiency. Indeed, in some 
experiments we could detect decreased phosphorylation levels of mTORC1 targets 
(Figure 4.9) suggesting that AMPK might regulate mTORC1 in response to energy stress 
following Vhl deletion (Inoki et al. 2003; Shaw et al. 2004; Liu et al. 2006). Unfortunately, 
these experimental findings proved difficult to reproduce, potentially because they occur 
only in a restricted time window after gene deletion or because other factors that we were 
not able to control in our experimental setup also influence AMPK activity, for example 
increased lactate concentrations in the medium or depletion of amino acids. 
 
We wondered whether Hif1α-mediated metabolic changes could cause energy stress, 
AMPK activation and downregulation of the mTORC1 pathway, leading to lowered rates 
of proliferation. Thus, a selection against AMPK and/or mTORC1 may represent the 
additional step for tumour initiation and progression in Vhl/Trp53 deficient cells. As 
already mentioned the PI3K-AKT-mTORC1 pathway is mutationally activated in a subset 
of sporadic ccRCC (Sato et al. 2013). Reduced AMPK activity or reduced expression of 
Prkaa2, the gene encoding AMPK, was found in human breast, ovarian and gastric 
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cancer (Hallstrom et al. 2008; Hadad et al. 2009; Kim et al. 2012). In sporadic ccRCC, 
decreased AMPK activity has been proposed to be involved in a metabolic shift that 
correlates with disease aggressiveness (TCGA 2013). Furthermore, for LKB1, the kinase 
upstream of AMPK, a tumour suppressor function in sporadic cases of ccRCC was 
predicted whereas its underexpression seems to be important for cancer progression, at 
least in cultured ccRCC cells (Duivenvoorden et al. 2013). Thus, there could be several 
possibilities by which AMPK function could be suppressed during the progression of 
ccRCC and the resulting cell signalling and metabolic changes may provide a growth 
advantage for cells. Different experiments with knockdowns of Tsc1, Tsc2, Stk11 or 
Prkaa1 in Vhl/Trp53 deficient MEFs could not further confirm this hypothesis as none of 
these knockdowns promoted enhanced proliferation or transformation of these cells 
(Figure 4.10A, 4.11A, 4.11E and 4.13A). Although all knockdown experiments showed 
increased phosphorylation levels of mTORC1 targets (Figure 4.10C, 4.11B, 4.11F and 
4.13F), it seems that other pathways which are affected by the loss of Vhl may have a 
stronger restriction on accelerated proliferation and transformation than the loss of AMPK 
and the resulting induction of mTORC1. Another interesting aspect in those experiments 
was that none of the knockdowns rescued ATP levels (Figure 4.10E, 4.13E). In 
conclusion, it seems that on top of Vhl and Trp53 mutation and an activation of the 
mTORC1 pathway additional mutations are required for tumour initiation. 
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5 Glutamine metabolism in Vhl-deficient cells 
5.1 Introduction and Aims 
Highly proliferating cells as well as cancer cells have special requirements: maintenance 
of their energy status through rapid ATP generation and of cellular redox status as well 
as an increase of macromolecule biosynthesis (Cairns et al. 2011). Glutamine is, besides 
glucose, the main bioenergetic substrate, providing carbon and nitrogen for cell growth 
and viability. Many cancer cells are critically dependent on glutamine for proliferation and 
survival (Wise and Thompson 2010). Hypoxic or VHL-deficient cancer cells almost 
exclusively use reductive carboxylation to metabolise glutamine-derived α-ketoglutarate 
to produce citrate for lipid biosynthesis (Metallo et al. 2011). The first step in 
glutaminolysis is the metabolism of glutamine to glutamate which is conducted by 
glutaminases. So far, four different isoforms have been identified in mammalian cells. 
They are encoded by two different genes, GLS1 with its two splicing forms KGA and 
GAC, as well as GLS2 with the two transcript variants GAB and LGA. Quite often only 
one of the four glutaminases is found in a specific organ or cancer cell line but also a co-
expression is possible (Aledo et al. 2000). In tumourigenesis the glutaminases have been 
shown to have contrasting roles. In contrast to GLS2, c-Myc regulated GLS1 promotes 
tumour progression when overexpressed (Gao et al. 2009; Hu et al. 2010). The loss of 
GLS1 prevents accelerated cell growth whereas decreased levels of GLS2, a p53 target 
gene, could be found in hepatocellular carcinomas (Lobo et al. 2000; Liu et al. 2014). 
 
Vhl/Trp53 negative cells show a similar metabolic phenotype to Vhl deficient cells in 
terms of a shift from oxidative phosphorylation towards glycolysis and decreased ATP 
levels. Interestingly however, these cells have overcome Vhl-induced senescence. We 
wondered if the senescence-rescued Vhl/Trp53 null cells might rely more on glutamine 
for anapleurosis to fuel their demands for energy and metabolic intermediates since 
glucose preferentially is converted to lactate and therefore cannot be metabolised in the 
oxidative TCA cycle.  
 
5.2 Results 
5.2.1 Hif1α-dependent regulation of glutaminase 
In a first step to investigate this idea, glutamine uptake was analysed by measuring the 
incorporation of radioactive labelled glutamine (14C5) in wild-type, Vhlfl/fl, Vhlfl/fl Trp53fl/fl and 
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Trp53fl/fl MEFs treated with Adeno-GFP or Adeno-Cre. However, no differences in the 
rate of glutamine uptake could be observed (Figure 5.1).  
 
 
 
Figure 5.1: Vhl deficiency does not affect glutamine uptake. 
Glutamine uptake was measured by incorporation of 14C5-labeled glutamine in wild-type, Vhlfl/fl, Vhlfl/fl Trp53fl/fl 
and Trp53fl/fl MEFs infected with adenoviruses expressing GFP or Cre. 
 
 
In a parallel experimental approach, genes were examined that are directly involved in 
glutamine uptake (Asct2), conversion (Gls1, Gls2, Glud1, Got1, Got2) and the TCA cycle 
(Idh1, Idh2, Aco1, Aco2) (see also Figure 1.2). No changes could be observed in the 
transcript levels of Asct2, Gls1, Glud1, Got1, Got2, Idh1, Idh2, Aco1 or Aco2 neither in 
Vhl nor in Vhl/Trp53 depleted MEFs (Figure 5.2A-D). However, the levels of Gls2 were 
significantly increased in Vhl and Vhl/Trp53 knockout MEFs (Figure 5.3A, B) and primary 
kidney cells (Figure 5.4A, B). Cells harbour four different forms of the enzyme 
glutaminase. To test which forms are expressed in primary MEFs and kidney cells 
primers specific for the different forms were tested. The used primer pair for Gls1 could 
detect both forms, Kga and Gac. Interestingly, the Gls2 isozyme Lga could not be 
detected in MEFs or in kidney cells (data not shown). The primer pairs Gls2 A and Gls2 
B specifically recognised Gab, Gls2 C and Gls2 D were able to detect Gab and Lga. As 
the changes in the expression levels with all four Gls2 primer pairs were similar, this 
confirmed that Lga was not expressed in primary MEFs and kidney cells (Figure 5.3A, B 
and 5.4A, B). In general in both cell types the transcript levels of Gls2 were lower 
compared to Gls1. Even with induced Gls2 in Vhl negative cells these levels were still 
lower than the levels of Gls1.  
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Figure 5.2: No induction of genes involved in reductive TCA cycle in Vhl or Vhl/Trp53 deficient MEFs. 
A-D Real-time quantitative PCR analysis of different genes that are involved in glutaminolysis in Vhlfl/fl (A), 
Vhlfl/fl Trp53fl/fl (B), Trp53fl/fl (C) and wild-type (D) MEFs infected with adenoviruses expressing GFP or 
Cre (Student´s t-test, *p < 0.05). 
 
So far very little is known about the regulation of Gls2. Two independent studies revealed 
that p53 associates with the GLS2 promoter and thus increases its expression in 
stressed and non-stressed conditions (Hu et al. 2010; Suzuki et al. 2010). In primary 
MEFs the levels of Gls2 were not reduced by the loss of Trp53 (Figure 5.3C). Moreover, 
since Vhl/Trp53 double knockout MEFs and primary kidney epithelial cells exhibit high 
levels of Gls2, we conclude that the induction of Gls2 following Vhl deletion is 
independent of p53. Since Gls2 was upregulated in Vhl and Vhl/Trp53 deleted cells, with 
stabilised Hif1α transcription factors (Albers et al. 2013), Vhlfl/fl Hif1afl/fl and Vhlfl/fl Hif2afl/fl 
cells were analysed. The deletion of Hif1a rescued the increased expression levels of 
Gls2 in a Vhl negative background (Figure 5.3E, 5.4D), whereas the loss of Hif2a in Vhl 
negative cells showed no effect (Figure 5.3F). This could be confirmed with the triple 
knockout MEFs Vhlfl/fl Hif1afl/fl Hif2afl/fl with rescued transcript levels of Gls2 (Figure 5.3G). 
The results indicate that a Hif1α-dependent mechanism is responsible for the regulation 
of Gls2 transcription.  
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Figure 5.3: Upregulation of Gls2 mRNA levels in Vhl and Vhl/Trp53 null MEFs. 
A-G Real-time quantitative PCR analysis of Gls1 and Gls2 mRNA abundance normalized to S12 mRNA 
abundance in Vhlfl/fl (A), Vhlfl/fl Trp53fl/fl (B), Trp53fl/fl (C), wild-type (D), Vhlfl/fl Hif1afl/fl (E), Vhlfl/fl Hif2afl/fl 
(F) and Vhlfl/fl Hif1afl/fl Hif2afl/fl (G) MEFs infected with adenoviruses expressing GFP or Cre. For the 
detection of Gls2 mRNA four different primer pairs were used labelled with Gls2 A-D (Student´s t-test, 
*p < 0.05, **p < 0.01). 
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Figure 5.4: Elevated Gls2 transcript levels in Vhl and Vhl/Trp53 deficient kidney cells. 
A-E Real-time quantitative PCR analysis of Gls1 and Gls2 mRNA abundance normalized to S12 mRNA 
abundance in Vhlfl/fl (A), Vhlfl/fl Trp53fl/fl (B), Trp53fl/fl (C), Vhlfl/fl Hif1afl/fl (D), and wild-type (E) kidney cells 
infected with adenoviruses expressing GFP or Cre. For Gls2 four different primer pairs were used 
labelled with Gls2 A-D (Student´s t-test, *p < 0.05).  
 
To further investigate the role of Hif1α in the modulation of Gls2 we treated cells for 
several hours with hypoxia as low oxygen levels stabilise the Hifα transcription factors. 
The treatment of cells with 1% oxygen for four, six or 30 hours had no effect on Gls2 
levels in wild-type cells (Figure 5.5A) and only in Vhl null cells a further induction could 
be observed after long-term hypoxia (Figure 5.5B-D). Hypoxia treatment had no effect on 
Gls1 levels in any of the cell types (Figure 5.6A-D). Taking these results together, the 
loss of Vhl causes an increase of the Gls2 transcript, which is Hif1α-dependent but not 
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hypoxia inducible. Unfortunately, it was not possible to confirm these observations at the 
protein expression level as several commercially available anti-Gls2 antibodies did not 
give any specific bands in western blotting experiments.  
 
 
 
Figure 5.5: Gls2 transcript levels are not hypoxia-inducible. 
A-D Real-time quantitative PCR analysis of Gls2 mRNA abundance normalized to S12 mRNA abundance in 
wild-type (A), Vhlfl/fl (B), Vhlfl/fl Trp53fl/fl (C) and Trp53fl/fl (D) MEFs infected with adenoviruses expressing 
GFP or Cre in 5% O2 or 1% O2 for 4h, 8h or 30h. 
E, F Western blotting analysis of cells from (A-D) with indicated O2 levels. 
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Figure 5.6: Hypoxia has no effect on Gls1 transcript levels. 
A-D Real-time quantitative PCR analysis of Gls1 mRNA abundance normalized to S12 mRNA abundance in 
wild-type (A), Vhlfl/fl (B), Vhlfl/fl Trp53fl/fl (C) and Trp53fl/fl (D) MEFs infected with adenoviruses expressing 
GFP or Cre in 5% O2 or 1% O2 for 4h, 8h or 30h. 
 
5.2.2 Loss of Gls2 provides a growth advantage for cells 
To further investigate the role of the Gls1 and Gls2 glutaminases in Vhl depleted cells, 
knockdown experiments using shRNAs directed against Gls1 and Gls2 were performed 
in Vhl/Trp53 null MEFs. The knockdown of Gls1 had no effect on the proliferation of 
Vhl/Trp53 negative cells but control cells (Adeno-GFP treated) grew marginally better 
than cells infected with non-silencing shRNA (Figure 5.7A). Interestingly, silencing of 
Gls2 caused a minor growth advantage for Vhl/Trp53 deficient MEFs as well as for 
control cells (Adeno-GFP treated) (Figure 5.7B). In immortalisation assays the Vhl/Trp53 
deleted MEFs with a Gls2 knockdown also formed more colonies (Figure 5.7F) and these 
cells were able to grow in an anchorage independent manner (Figure 5.7G). As an 
additional control, we investigated whether the knockdown of Gls2 could be 
compensated by an increased expression of Gls1 and vice versa. Real time quantitative 
PCR analysis revealed that no compensatory events took place (Figure 5.7D, E). These 
preliminary experiments suggest that Gls2 activation prevents the efficient transformation 
of Vhl/Trp53 double mutant cells. More experiments are now necessary to further 
investigate the role of Gls2 and its effects on the transformation of Vhl negative cells. 
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Figure 5.7: Anchorage independent growth after deletion of Gls2 in Vhl/Trp53 negative MEFs. 
A, B Proliferation assay of Vhlfl/fl Trp53fl/fl MEFs infected with adenoviruses expressing GFP or Cre and 
lentiviruses expressing an empty pLKO.1 shRNA (shRNA-ns) or pLKO.1 shRNA directed against Gls1 
(A) or Gls2 (B) (shRNA-Gls1 or Gls2). 
C  Western blotting analysis of cells from (A) and (B) at indicated time points. 
D, E Real-time quantitative PCR analysis of Gls1 (D) and Gls2 (E) mRNA abundance normalized to S12 
mRNA abundance in cells from (A) and (B). 
F Immortalisation assay of cells from (A) and (B). 
G Anchorage independent growth of cells from (B). Scale bar 50 µm. 
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5.3 Discussion 
In proliferating tumour cells glutamine is an essential nutrient, participating in oxidative 
stress responses, in the maintenance of the cellular energy status and in complementing 
macromolecular biosynthesis by providing a source of carbon and nitrogen (DeBerardinis 
and Cheng 2010). Interestingly, many cancer cells are critically dependent on glutamine 
for proliferation and survival (Wise and Thompson 2010). Proliferating cells in normoxia 
use glucose-derived acetyl-CoA or oxidative metabolism of glutamine to support citrate 
production, whereas hypoxic or VHL-deficient cancer cells almost exclusively use 
reductive carboxylation to metabolise glutamine-derived α-ketoglutarate to produce 
citrate for lipid biosynthesis (Metallo et al. 2011; Wise et al. 2011; Gameiro et al. 2013). 
This pathway is dependent on HIF1 activity and results in the reduction of the activity of 
α-KGDH (α-ketoglutarate dehydrogenase) which normally acts to convert α-ketoglutarate 
to succinyl-CoA, supplying carbons for anapleurotic glutamine metabolism via the TCA 
cycle. Shutting down this anapleurotic oxidative glutamine metabolism is proposed to 
enhance reductive glutamine metabolism (Sun and Denko 2014). We tried to answer the 
question if the senescence-rescued Vhl/Trp53 null cells might use carbons derived from 
glutamine to fuel their demands for energy and metabolic intermediates. The mRNA 
levels of genes that are responsible for glutaminolysis and reductive carboxylation, 
including Asct2, Gls1, Glud1, Got1, Got2, Idh1, Idh2, Aco1 or Aco2, were not changed in 
MEFs deficient for Vhl and Vhl/Trp53 (Figure 5.2), suggesting that they are not 
responsive to stabilisation of Hifα proteins. A similar result was shown in UMRC2 cells, a 
kidney carcinoma cell line negative for VHL, which uses reductive carboxylation of 
glutamine, where these genes were also not more highly expressed than in a VHL 
rescued cell line (Gameiro et al. 2013). However, it cannot be ruled out that Hifα protein 
stabilisation might still have an effect on the activity of these enzymes possibly via post-
transcriptional modifications or by effecting other metabolic changes that alter the 
availability of cofactors. Metabolomic analysis of cells negative for Vhl and Vhl/Trp53 did 
not show any accumulation of glutaminolytic metabolites (Figure 3.4). To find convincing 
answers to the question if Vhl/Trp53 negative cells use reductive carboxylation, 
metabolic flux analysis would be necessary to fully trace the metabolism of glutamine. 
Also, to exactly determine the intracellular pathways of glucose metabolism this would be 
a helpful tool. For these experiments, cells would be starved for a short time period for 
glucose or glutamine before radioactive labelled glucose or glutamine is introduced to the 
cells. Dependent on the way glucose or glutamine are metabolised in the cell different 
metabolites accumulate. These radioactive labelled metabolites can then be determined 
by GC-MS. For example, with the tracing of labelled glucose we could determine if 
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glucose is more metabolised in the pentose phosphate pathway or is preferentially 
metabolised directly via glycolysis to lactate.   
 
An interesting finding in MEFs and kidney cells deficient for Vhl and Vhl/Trp53 was that 
Gls2 transcript levels were elevated in a Hif1α-dependent manner (Figures 5.3 and 5.4). 
We could not detect a consensus hypoxia-response element (HRE) in the promoter 
region of Gls2, suggesting that Gls2 is not a direct transcriptional target of Hif1α. The 
levels of Gls2 were also not hypoxia inducible (Figure 5.5) suggesting that other 
mechanisms caused by the loss of Vhl might be important. Gls2 is expressed due to p53 
activation in MEFs and human colon, breast and lung cancer cell lines. Also the p53 
family members p63 and p73 regulate Gls2 expression in keratinocyte differentiation or 
during neuronal differentiation, respectively (Hu et al. 2010; Suzuki et al. 2010; Giacobbe 
et al. 2013; Velletri et al. 2013). Upon p53 activation, Gls2 contributes to reduced ROS 
levels and enhanced oxygen consumption, mitochondrial respiration and ATP generation 
(Hu et al. 2010; Suzuki et al. 2010). In the context of Vhl-deficiency, p53 has no influence 
on Gls2 levels as p53 is not activated in those cells (Figure 4.5) and Vhl/Trp53 negative 
cells still show elevated Gls2 levels (Figure 5.3B and 5.4B). 
 
As the upregulation is seen in Vhl negative cells and in the senescence-rescued 
Vhl/Trp53 deficient cells, which still proliferate less than cells that lost Trp53 alone, we 
speculated that Gls2 might negatively influence proliferation. Preliminary knockdown 
experiments of Gls2 in Vhl/Trp53 deficient MEFs suggest that this hypothesis might be 
correct as these cells proliferated better than Vhl/Trp53 negative cells alone and they 
could grow in an anchorage independent manner (Figure 5.7). Further experiments using 
multiple independent shRNAs targeting Gls2 are now underway to further support this 
unexpected finding that elevated Gls2 expression may exert a tumour suppressor-like 
activity in Vhl mutant cells. It would be interesting to investigate whether Vhl/Trp53 
negative cells with a knockdown of Gls2 could grow as xenografts. Consistent with our 
preliminary findings, different studies have predicted a potential role for GLS2 in tumour 
suppression. In hepatocellular carcinoma and many brain tumours the levels of GLS2 
were decreased or lost and re-expression reduced or inhibited tumour cell proliferation 
(Szeliga et al. 2009; Hu et al. 2010; Suzuki et al. 2010). 
 
Cells with stabilised Hif1α (hypoxic or VHL-deficient) use glutamine-dependent reductive 
carboxylation to support citrate and lipid biosynthesis (Metallo et al. 2011). The kinetic 
properties of the different glutaminases are diverse. GLS2 shows, in contrast to GLS1, 
no inhibition by glutamate, the product of its enzymatic reaction (Curthoys and Watford 
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1995). Thus, it might be speculated that an increase in GLS2 expression might allow 
higher levels of glutaminolysis, which could be needed for reductive carboxylation. As 
HIF promotes reductive glutamine metabolism a potential regulatory mechanism between 
Hif1α and Gls2 would be conceivable. Further analyses are necessary to investigate the 
mechanism of Hif1α-dependent regulation of Gls2 and the functional implications of the 
change in expression of this enzyme.  
 
To date, no research was conducted on GLS2 expression or function in kidney tumours 
or renal cancer cell lines. Aledo and colleagues could not detect GLS2 levels in human 
kidneys (Aledo et al. 2000). One possibility therefore could be that in unstressed 
conditions GLS2 expression is extremely low and an increase of GLS2 levels represents 
a mechanism that follows VHL mutation and suppresses early tumour development that 
needs to be overcome for further tumour progression. In contrast, in diverse mouse 
genetic backgrounds we found that mRNA levels of Gls2 were detectable in the kidney at 
levels similar to levels seen in MEFs (data not shown). It will be now interesting to 
investigate if there is a role for Gls2 in tumour prevention in renal cancer by investigating 
the dependency of GLS2 expression in VHL deficient and VHL rescued ccRCC cell lines 
on HIF1α and HIF2α. Another question that has to be answered is whether early lesions 
in mouse and human kidneys exhibit elevated Gls2/GLS2 protein levels and whether 
GLS2 expression might be reduced or lost in a subset of human ccRCC.  
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6 Cooperation of loss of Vhl and Rb1 in tumour initiation 
6.1 Introduction and Aims 
An important tumour suppressor that is involved in cell cycle and senescence regulation 
is the retinoblastoma protein. During cell cycle pRB is phosphorylated and inactivated by 
cyclin/Cdk complexes. Thereby, E2F proteins are released from pRB and can function as 
transcription regulators. The cyclin/Cdk complexes are in turn regulated by CDK 
inhibitors such as p21Cip and p27Kip. These two proteins exhibit elevated levels upon 
deletion of Vhl in transformed MEFs (Mack et al. 2005). pRb also has been implicated in 
the regulation of senescence following loss of Vhl in primary MEFs (Young et al. 2008). 
Loss of function mutation of RB1 is a common event in the development of many tumour 
types. In a sub-fraction of human ccRCC, genetic alterations of the RB1 gene have been 
detected (Ishikawa et al. 1991; Shuin et al. 1995; Lai et al. 1997). Recent studies in 
sporadic ccRCC revealed multiple alterations in components of senescence and cell 
cycle machinery pathways including RB1 and its direct target E2F3 (Sato et al. 2013).  
 
Our aim was to generate an inducible kidney epithelial cell-specific combined deletion of 
Vhl and Rb1 to study potential cooperative effects of loss of function of these genes on 
ccRCC development. Furthermore, primary cell culture studies with cells derived from 
Vhlfl/flRb1fl/fl mice were utilised to examine the role of Rb1 deletion in a Vhl negative 
background.  
 
6.2 Results 
6.2.1 Deletion of Rb1 rescues Vhl induced senescence and ATP deficiency 
in mouse embryonic fibroblasts 
For ex vivo studies we generated primary mouse embryonic fibroblast from the mice 
described in 6.2.2. Since pRb seems to be important for the regulation of cell cycle and 
senescence pathways, we tested whether the loss of protein expression is beneficial for 
Vhl deficient cells. The growth disadvantage of Vhl null cells was partially rescued due to 
combined deletion of Vhl and Rb1 but these cells proliferated less than Rb1 knockout 
cells alone (Figure 6.1A), a similar phenotype to that observed in Vhl/Trp53 double 
mutant cells. Both, Vhl/Rb1 and Rb1 negative cells were immortalised (Figure 6.1E) but 
only Vhl/Rb1 deficient MEFs were able to grow in an anchorage independent manner 
(Figure 6.1C). Cells deficient for Vhl undergo senescence and activate a Warburg-like 
metabolic phenotype with shifted glucose utilisation and decreased ATP levels. 
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Senescence-rescued Vhl/Trp53 negative cells still exhibit reduced ATP levels 
(Figure 4.2F). The loss of Vhl also gives rise to elevated glycolytic genes and a shift form 
oxidative phosphorylation to glycolysis (Figure 4.1A, B). Interestingly, the combined loss 
of Vhl and Rb1 restored the ATP levels in primary MEFs (Figure 6.1D). However, 
glycolytic genes like Glut1 and Pfkfb3 were still upregulated (Figure 6.2B). Further 
experiments are now required to understand how these metabolic changes arise and 
what their influence is on cell transformation. Comparison of Vhl/Trp53 and Vhl/Rb1 
negative cells reveals that senescence induced by loss of Vhl is rescued in both, and 
both exhibited elevated glycolytic genes, yet only Vhl/Rb1 deficient MEFs display 
rescued ATP levels and were able to grow anchorage independently.  
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Figure 6.1: Deletion of Rb1 rescues senescence and ATP levels in Vhl negative MEFs. 
A Proliferation assay of Vhlfl/fl, Vhlfl/fl Rb1fl/fl and Rb1fl/fl MEFs infected with adenoviruses expressing GFP 
or Cre. 
B Western blotting analysis of cells from (A) at indicated time points. 
C Anchorage independent growth of Vhl-/- Rb1-/- cells from (A). Scale bar 50 µm. 
D Cellular ATP levels of cells from (A) 5 days after adenovirus infection. 
E Immortalisation assay of cells from (A). 
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Figure 6.2: Glycolytic genes are also upregulated in Vhl/Rb1 negative MEFs. 
A-C Real-time quantitative PCR analysis of Vhlfl/fl (A), Vhlfl/fl Rb1fl/fl (B) and Rb1fl/fl (C) MEFs infected with 
adenoviruses expressing GFP or Cre. mRNA abundance of shown genes was normalized to S12. 
 
A recent study from (Reynolds et al. 2014) revealed that glutamine metabolism is 
controlled by the retinoblastoma protein family. The combined loss of Rb1/p130/p107 in 
MEFs resulted in increased glutamine uptake caused by higher expression of the 
glutamine transporter Asct2 via releasing E2F3 from Rb. Furthermore, the activity of Gls1 
was elevated and glutathione synthesis was increased in these cells. Therefore, we 
investigated whether the Vhl/Rb1 deficient cells with rescued ATP levels exhibit changes 
in glutamine metabolism. Genes were analysed that are involved in glutaminolysis such 
as Asct2, Gls1, Gls2, Glud1, Got1 and Got2. The levels of Asct2 were neither in Vhl/Rb1 
nor in Rb1 negative MEFs changed (Figure 6.3B, C) and also none of the other 
glutaminolytic genes showed any differences compared to control cells. Interestingly, 
Gls2 levels were elevated in Vhl/Rb1 knockout cells (Figure 6.3B) but not in Rb1 deficient 
MEFs (Figure 6.3C). Since we also observed elevated Gls2 levels in Vhl and Vhl/Trp53 
negative cells, both with deficient ATP levels and since the loss of Gls2 provided a 
growth advantage for Vhl/p53 negative cells and allowed them to grow anchorage 
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independently, further experiments are now necessary to define the function of Gls2 in 
transformed Vhl/Rb1 negative cells.   
 
 
 
Figure 6.3: Transcript levels of Gls2 elevated in Vhl/Rb1 deficient cells. 
A-C Real-time quantitative PCR analysis of Vhlfl/fl (A), Vhlfl/fl Rb1fl/fl (B) and Rb1fl/fl (C) MEFs infected with 
adenoviruses expressing GFP or Cre. mRNA abundance of shown genes was normalized to S12. 
 
6.2.2 Kidney cancer model 
Given our observation of genetic cooperation between Vhl and Rb1 in cell culture and the 
presence of RB1 pathway alterations in ccRCC, we generated mice with a tamoxifen-
inducible kidney-specific deletion of Rb1 alone (Ksp1.3-Cre-ERT2 Tg/+; Rb1fl/fl) as well as in 
combination with Vhl (Ksp1.3-Cre-ERT2 Tg/+; Vhlfl/fl; Rb1fl/fl). As control animals littermate 
mice that were negative for the Ksp1.3-Cre-ERT2 transgene were used (Ksp1.3-Cre-
ERT2 +/+). Therefore, Ksp1.3-Cre-ERT2 mice were crossed with Rb1fl/fl and Vhlfl/fl Rb1fl/fl 
mice containing loxP sites inserted in the genomic DNA. Transgenic Ksp1.3-Cre-ERT2 
mice contain the fusion protein Cre-ERT2 that is under the control of the Ksp-cadherin 
gene promoter. The Cre-ERT2 protein is retained in its inactivated form in the cytosol and 
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is activated upon binding of 4-hydroxytamoxifen, translocated to the nucleus and 
mediates Cre/loxP recombination. The Ksp1.3-Cre promoter is a kidney specific 
transgene that generates a deletion of floxed genes in the epithelial cells at the urinary 
pole of the glomerulus, distal tubules, loops of Henle, collecting ducts and also more 
rarely in proximal tubular cells (Feil et al. 1997; Shao et al. 2002; Shao et al. 2002). To 
study the effects of inactivation of Rb1 and Vhl/Rb1 in mice, control and Cre-expressing 
Rb1fl/fl and Vhlfl/fl Rb1fl/fl mutant mice were exposed to tamoxifen. Nursing dams were 
injected intra peritoneal with tamoxifen two days after giving birth (P2) or animals were 
directly injected eleven days after birth (P11) or at four weeks of age (4W). The different 
injection time points were chosen to test whether there is a difference in the onset of cyst 
and tumour development caused by decreased cell proliferation in older mice. Several 
studies revealed that cyst progression was dependent on the time point when the 
deletion of Kif3a, a kinesin II subunit important for ciliogenesis, was initiated. Animals 
injected before P11 had a fast cyst progression within four weeks, whereas after P11 
cyst development occurred after six month of age (Davenport et al. 2007; Patel et al. 
2008). Treated animals are hereafter referred to as Rb1∆/∆, Vhl∆/∆Rb1∆/∆ and controls as 
Rb1fl/fl, Vhlfl/fl Rb1fl/fl, respectively. Animals were analysed at the age of 2-3 months 
(Rb1∆/∆: P2: n = 2; Vhl∆/∆Rb1∆/∆: 4W: n = 4), 5-8 months (Rb1∆/∆: 4W: n = 5, P2: n = 4; 
Vhl∆/∆Rb1∆/∆: 4W: n = 5, P2: n = 4) and 11-13 months (Rb1∆/∆: 4W: n = 3, P2: n = 17, 
P11: n = 6; Vhl∆/∆Rb1∆/∆: 4W: n = 1, P2: n = 9). Control, Rb1∆/∆ and Vhl∆/∆Rb1∆/∆ mice 
exhibited normal kidney histology within three months after tamoxifen treatment (data not 
shown). It could be clearly shown that the recombination of Vhl and Rb1 occurred but 
with high variance between different animals (Figure 6.4M-R). However, at the age of five 
months small clusters of disorganised cells could infrequently be observed in Rb1∆/∆ and 
Vhl∆/∆Rb1∆/∆ animals but not in control animals (Figure 6.4A-C). At the age of one year, 
Rb1∆/∆ mutant animals infrequently displayed micro-cysts but this could only be observed 
in less than 50% of analysed animals (Rb1∆/∆: 4W: n = 3; P2: n = 17; P11: n = 6) 
(Figure 6.4D-I). Interestingly, the double knockout mice had an almost normal histological 
appearance aside from very infrequent clusters of disorganised cells that already could 
be seen in younger mice and atypical nuclei (Vhl∆/∆Rb1∆/∆: 4W: n = 1; P2: n = 9) 
(Figure 6.4J-L). Thus, no neoplastic transformation took place with advanced age. In 
summary, these mouse studies with combined loss of Vhl and Rb1 in kidney epithelial 
cells revealed no cyst or tumour formation, suggesting that additional mutations might 
have to occur to initiate enhanced cell proliferation. However, as the Rb1∆/∆ mice display 
micro-cysts and this phenotype is completely gone in Vhl∆/∆Rb1∆/∆ animals it seems that 
the loss of Vhl prevents rather than accelerates growth of hyperplastic lesions.    
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Figure 6.4: Rb1∆/∆ and Vhl∆/∆Rb1∆/∆ mice display no cyst or tumour formation in kidneys.  
Scale bars depict 50 µm. A, D-H, O, R are the same magnification. B-C, J-N, P-Q are the same 
magnification. 
A-C Histological appearance of cortex of kidneys from 5-8 month-old wild-type (A), Rb1∆/∆ (B) and 
Vhl∆/∆Rb1∆/∆ (C) mice. 
D-I Examples of micro-cysts found in kidneys of 1-year-old Rb1∆/∆ mice. 
J-L Histological appearance of cortex of kidneys from 1-year-old Vhl∆/∆Rb1∆/∆ mice.  
M-R anti-Rb1 and anti-Hif1α immunohistochemistry of 1-year-old Vhl∆/∆Rb1∆/∆ mice. 
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We showed that Vhl∆/∆Trp53∆/∆ mice exhibit a dysregulation of epithelial cell proliferation, 
thus developing simple cysts, atypical cysts and neoplasms in the kidneys (Albers et al. 
2013). However, the latency for development of cysts and tumours was one year, 
indicating that other mutations are most likely necessary for initiation of these lesions. 
Given our cell culture data indicating a cooperative effect of combined Vhl and Rb1 
mutation in senescence-rescue, ATP-rescue and induction of anchorage-independent 
growth we also generated mice with a tamoxifen-inducible kidney-specific deletion of Vhl, 
Rb1 and Trp53 (Ksp1.3-Cre-ERT2 Tg/+; Vhlfl/fl; Rb1fl/fl; Trp53fl/fl) as well as of Rb1 and Trp53 
(Ksp1.3-Cre-ERT2 Tg/+; Rb1fl/fl; Trp53fl/fl). Littermate mice negative for the Ksp1.3-Cre-ERT2 
transgene were used as control animals (Ksp1.3-Cre-ERT2 +/+). The breeding for Ksp1.3-
Cre-ERT2 Tg/+; Rb1fl/fl; Trp53fl/fl animals is still ongoing. To generate knockout animals, 
nursing dams were injected with tamoxifen two days after giving birth (P2). Treated 
animals are hereafter referred to as Vhl∆/∆Rb1∆/∆Trp53∆/∆ and controls as 
Vhlfl/fl Rb1fl/fl Trp53fl/fl, respectively. The first Vhl∆/∆Rb1∆/∆Trp53∆/∆ animals were analysed at 
the age of three months (P2: 3 littermates). Vhlfl/fl Rb1fl/fl Trp53fl/fl control mice and one 
Vhl∆/∆Rb1∆/∆Trp53∆/∆ animal did not show any histological abnormalities (Figure 6.5A). 
The other two Vhl∆/∆Rb1∆/∆Trp53∆/∆ animals exhibited neoplasms, which grew in a solid or 
cystic pattern, some with clear cell appearance and some with nuclear atypia, suggestive 
of precursor lesions of ccRCC (Figure 6.5B-O). In ongoing experiments, aged cohorts of 
Vhl∆/∆Rb1∆/∆Trp53∆/∆ and Rb1∆/∆Trp53∆/∆ mice will be analysed to determine whether 
these precursor lesions can progress to form ccRCC and if these are dependent on loss 
of pVhl function.  
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Figure 6.5: Precursor lesions of ccRCC in kidneys of Vhl∆/∆Rb1∆/∆Trp53∆/∆ mice. 
Scale bars depict 50 µm. B-J are the same magnification. A, K-N are the same magnification. 
A Histological appearance of cortex of kidneys from 3 month-old wild-type mice. 
B-O Examples of lesions found in kidneys of 3 month-old Vhl∆/∆Rb1∆/∆Trp53∆/∆ mice. 
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6.3 Discussion 
The cell cycle and senescence regulator pRb has been indirectly implicated in the 
regulation of senescence following loss of Vhl in primary MEFs (Young et al. 2008). 
Recent studies in sporadic ccRCC revealed multiple alterations in components of the 
senescence and cell cycle machinery pathways, including RB1 and its direct target E2F3 
(Sato et al. 2013). We therefore examined the effect of combined loss of Vhl and Rb1 on 
cellular senescence and cellular metabolism following loss of pVhl function. In 
proliferation assays, Vhl/Rb1 negative MEFs showed a similar phenotype to Vhl/Trp53 
deficient MEFs. In both genotypes the senescence induced by loss of Vhl was rescued 
(Figure 6.1A) (Albers et al. 2013), but unlike Vhl/Trp53 negative cells, Vhl/Rb1 deficient 
MEFs showed rescued ATP levels and were able to grow in an anchorage independent 
manner, a hallmark of cellular transformation (Figure 6.1C and D). A recent study with 
Rb1/Rbl-1/Rbl-2 knockout MEFs could show a control function of Rb in glutamine 
metabolism (Reynolds et al. 2014). Therefore, it might be possible that Vhl/Rb1 deficient 
cells use glutamine to fuel the TCA cycle with carbons and thus can restore ATP. 
However, analyses of mRNA levels of glutaminolytic genes provided no further insights in 
this respect (Figure 6.3). As in the Vhl MEFs, Vhl/Rb1 cells also showed increased Gls2 
transcript levels (Figure 6.3). Further analysis will now be necessary to detect whether 
these cells take up more glutamine and to determine how it is metabolised. It will also be 
interesting to see if the oxygen consumption is rescued in Vhl/Rb1 deficient cells and 
whether this in turn influences cellular ATP levels. Furthermore, starvation assays are 
another experimental possibility to detect whether glutamine is necessary for the 
enhanced proliferation of Vhl/Rb1 negative cells. Another cause for the rescued ATP 
levels could be that the loss of Rb1 enhances glycolytic flux. A recent publication showed 
that Rb is part of the Rb-TRIP230-ARNT complex that mediates Hif1-activated gene 
expression and the loss of Rb enhanced Hif1-regulated transcription (Labrecque et al. 
2014). However, in contrast to this idea the analysed glycolytic genes in Vhl/Rb1 
deficient cells did not indicate a connection between Rb1 and Hif1 as their mRNA levels 
were not more elevated than in Vhl negative cells (Figure 6.2). Another question that has 
to be elucidated is why the Vhl/Rb1 negative MEFs can grow anchorage independently. 
Could the rescued ATP levels play a role in this phenotype? Detached epithelial cells 
exhibit reduced glucose transport and decreased ATP levels in comparison to attached 
cells and this has been proposed to prevent their proliferation in a type of attachment-
sensitive metabolic checkpoint (Schafer et al. 2009). This could be either rescued 
through overexpression of Erbb2 which enhanced glucose flux through stabilisation of 
PI3K and EGFR in a pentose phosphate pathway-dependent manner or via antioxidant 
treatment dependent on enhanced fatty acid oxidation without a rescue of glucose flux. 
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Both treatments enabled these cells to grow anchorage independently after rescuing 
ATP levels (Schafer et al. 2009). It will be now interesting to explore if Rb1 deletion has 
similar effects on Vhl deficient MEFs. 
 
Given our observation of genetic cooperation between Vhl and Rb1 in cell culture and the 
presence of RB1 pathway alterations in ccRCC, another aim of this thesis was to 
generate kidney-specific combined deletion of Rb1 and Vhl to study potential cooperative 
effects of loss of function of these genes on ccRCC development. Despite promising 
results from cell culture studies, the kidney-specific deletion of Vhl and Rb1 did not lead 
to the breakdown of normal proliferation in mice. While Rb1∆/∆ animals showed micro-
cysts and small foci of tubular dysplasia, the additional loss of Vhl in fact prevented the 
growth of hyperplastic lesions (Figure 6.4). Potentially, additional mutations might be 
necessary to initiate tumour development. In this context, our first analyses of mice 
harbouring combined deletion of Vhl, Trp53 and Rb1 provide very promising results. 
Already at the age of three months neoplasms could be found, which grew in a solid or 
cystic pattern, some with clear cell appearance and some with nuclear atypia 
(Figure 6.5). This histological appearance could potentially indicate precursor lesions of 
ccRCC. These lesions are already larger and occur at a much higher frequency about 
nine months earlier than the lesions that were observed in Vhl/Trp53 null mice. The 
analysis of aged cohorts of Vhl∆/∆Rb1∆/∆Trp53∆/∆ mice will show whether these precursor 
lesions can progress to form ccRCC. The use of control Rb1∆/∆Trp53∆/∆ mice will allow us 
to answer the question if the loss of Vhl is necessary for the development of these 
lesions and ccRCC. The Ksp1.3-Cre promoter is active in different kidney epithelial cells 
such as urinary pole of the glomerulus, distal tubules, loops of Henle, collecting ducts 
and also in proximal tubular cells. The exact determination of the cells of origin that gave 
rise to the different kinds of precursor lesions will be quite important, especially as the 
cell type(s) that gives rise to ccRCC is still unknown. Co-stainings with specific tubule 
markers and Hif target genes, to confirm Vhl deletion, will be helpful tools. Furthermore, it 
will be important to elucidate the status of primary cilia in these lesions. pVHL is involved 
in the suppression of cyst formation through the maintenance of primary cilia. In human 
VHL patients, as well as in the Vhl∆/∆Trp53∆/∆ mouse model, reduced cilia frequencies 
were seen in simple cystic lesions (Thoma et al. 2007; Albers et al. 2013). Thus, it would 
be interesting to confirm this initial cyst formation model with the triple knockout animals. 
The development of the neoplastic state observed in Vhl/Trp53 mutant mice correlated 
with upregulated c-Myc expression and hyperactivation of mTORC1 signalling (Albers et 
al. 2013). As the upregulation of mTORC1 or C-MYC predict poor patient outcome in 
human ccRCC patients it would be interesting to elucidate the levels of these proteins 
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and their associated signalling pathways in the triple knockout animals as it may be that 
these cooperating mutations could act to initiate and promote tumour formation.  
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7 General Discussion and Outlook 
The overall aim of this thesis was to begin to close some of the large knowledge gaps in 
understanding the molecular and cellular mechanisms that cause clear cell renal cell 
carcinoma. We used mice and primary cell culture systems to pursue the question of 
which mechanisms when disrupted can cause dysregulation of cell proliferation. This 
knowledge of the signalling pathways that underlie ccRCC development and progression 
is essential for thinking about rationally designed potential therapeutic targets. To 
approach this question we chose primary mouse embryonic fibroblasts as a culture 
system due to their ease of culturing and genetic manipulation. Compared to cancer cell 
lines which have an unknown variety of mutations we are able to specifically introduce 
defined mutations. We could prove that Vhl deficient cells show a Warburg-like 
phenotype. Even with a mutated second tumour suppressor gene such as Trp53 the 
Warburg effect was not fully developed in that there was only a relatively modest 
increase in glucose uptake that lead to a state of cellular energy stress, which potentially 
limits further transformation of these cells. However, in this project we were unable to 
identify the additional mutations that are necessary to initiate transformation of these 
cells.  
 
Another faster approach to identify pro-proliferative mutations on top of Vhl and Trp53 
could be to employ loss and gain of representation screenings. Thereby, shRNA-based 
screenings can be used to knockdown either the whole genome or selected sets of 
genes, like the kinome, or genes that regulate different signalling pathways, for example 
cell cycle controlling genes. With deep sequencing approaches we are then able to 
simultaneously discover the effects of knockdown of several hundred genes on 
proliferation of cells of the Vhl/Trp53 deficient background. In these experiments the cells 
would be infected with the desired library of shRNAs and either infected with adenovirus 
expressing GFP or Cre. During culturing of the knockout cells shRNA vectors of genes 
whose knockdowns cause inhibition of proliferation or cell death will rapidly be lost and 
are therefore under-represented in the deep-sequencing of the entire population of 
integrated shRNAs. shRNA vectors that are over-represented in the sequencing results 
indicate that the knockdown of these genes induces a proliferative advantage. Besides 
shRNAs, it would be also possible to use other systems like libraries based on the RNA-
guided CRISPR-Cas9 nuclease system that allows generation of gene knockouts in 
mammalian cells (Ran et al. 2013). In follow up experiments, any hits obtained could be 
individually validated in MEFs or primary epithelial kidney cells. A special interest focuses 
on their influence on the metabolism as we hope to clarify if the reduced ATP levels in 
Vhl/Trp53 deficient MEFs inhibit further proliferation. To further validate the results in a 
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more physiological setting, mutated MEFs or kidney cells could be injected into mice for 
xenograft assays. Another possibility would be to directly introduce the desired mutations 
into mouse kidneys. In our lab a lentiviral-based vector system, called MuLE (Multiple 
Lentiviral Expression), was developed which allows us to simultaneously introduce 
multiple genetic alterations into mammalian cells in vivo and ex vivo. This system 
enables us to generate complex polycistronic lentiviruses, which can combine 
constitutive or inducible gene knockdown, deletion or overexpression. In addition, 
fluorescent (eGFP, tdTomato, mCherry, iRFP) or enzymatic reporters (lacZ, luciferase) 
which can be used for animal imaging studies or cellular assays can be expressed as 
well (Albers et al. 2014). With this system we are able to combine shRNAs against Vhl 
and Trp53 with the shRNAs found in the screening described above and an enzymatic 
reporter such as luciferase and can directly inject the produced virus in mouse kidneys. 
With the enzymatic reporter, we would then be able to follow potential tumour 
development over time. Furthermore, the potential ability to generate different types of 
genetically defined mouse ccRCC tumour models using this system would also allow us 
to exactly monitor the process and efficacy of administered therapeutics.  
 
ccRCC remains one of the few major human cancer types for which no autochthonous 
mouse model exists. With the generated triple Vhl/Rb1/Trp53 knockout mouse model we 
hope that we will be able to specifically examine the different phases of tumour initiation 
and progression. The development of an accurate mouse model of ccRCC would be of 
high value as the current treatment options for ccRCC patients are quite limited and 
largely ineffective. The primary treatment modality of ccRCC confined to the kidney and 
its regional lymph nodes and vasculature is nephrectomy or if possible nephron-sparing 
surgery. However, at the time of diagnosis metastatic ccRCCs were found in 30% of 
patients. A similar percentage of patients develop metastasis during further cancer 
progression (Motzer et al. 1996; Leibovich et al. 2003). The symptom burden of 
metastatic ccRCC is extremely high and it is a rapidly fatal disease. So far, different 
tested treatment strategies, such as cytotoxic and hormonal therapy, had little success 
(Harris 1983; Yagoda and Bander 1989). In contrast, cytokine therapy with interferon-α 
and interleukin-2 promised at least for a sub-fraction of patients a positive effect (Motzer 
et al. 2002). The latest systemic therapies for ccRCC are based on new insights into 
signalling pathways that are affected in this disease such as VHL and mTORC1 
pathways. Their main aim is to target VEGF-mediated angiogenesis either via tyrosine 
kinase inhibitors, monoclonal antibodies or mTOR inhibitors. However, the therapeutic 
efficacy of these “new” agents is also not high and it is almost always non-curative and 
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associated with significant side effects (Fisher et al. 2013). With the generation of a 
mouse model we hope to be able to provide a better tool to test new therapeutic agents.  
 
We have developed a micro-computed tomography (µCT) imaging system that will be 
useful for the study of tumour development in our mouse model. The CT is a 3D x-ray 
imaging technique which is used to obtain x-ray projection images around the axis of an 
object. It generates a pile of thin tomographic images of adjacent slices through the body. 
This method can be applied to follow in vivo processes in animals such as myocardial 
infarction (Badea et al. 2008), metastasis (Ohta et al. 2006) and kidney volume 
(Almajdub et al. 2008). In our lab it also could be shown to be an efficient tool to follow 
longitudinal studies of cyst formation and progression in mouse kidneys using an injected 
contrast agent (Lehmann et al. 2014). We will employ our Vhl/Rb1/Trp53 mouse model 
and utilise µCT imaging at different time points to determine how and when tumours are 
initiated and how rapidly they progress in this model. If it is possible in living mice to 
quantitatively follow the tumour progression with the µCT, we would then aim to apply 
specific therapeutic agents at different tumour stages and the efficacy of the treatment 
could easily be traced via non-invasive imaging.  
 
Using whole genome DNA sequencing analyses of lesions that arise in Vhl/Rb1/Trp53 
mice we would be able to detect other genetic alterations, which potentially cooperate at 
different tumour stages with the induced mutations, possibly promoting tumour 
progression. Alternatively or additionally, sequencing platforms could be used which 
amplify based on PCR analyses discrete regions of the genome. The genomic DNA can 
be isolated by laser capture microdissection from formalin-fixed paraffin-embedded 
tumour tissue. As this system can work with a low amount of DNA, specific tumour 
regions can be isolated and analysed separately for mutations in sets of genes to 
investigate questions of intratumoural heterogeneity.  
 
Cell lines derived from different tumour stages of triple knockout mice could provide 
another useful tool for new therapeutic strategies. These cell lines could be used to 
screen chemical libraries to search for new therapeutic targets. Furthermore, the above 
described genetic sequencing analyses could also be conducted in these cell lines and 
the obtained results may help to develop better treatment strategies. Thus, a ccRCC 
mouse model that accurately reproduces the genetic and cellular features of the human 
disease would tremendously contribute to the understanding of the mechanisms 
underlying ccRCC initiation and progression and to the development of new therapeutic 
strategies. 
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